Spaces:
Running
Running
File size: 116,592 Bytes
9754890 |
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 449 450 451 452 453 454 455 456 457 458 459 460 461 462 463 464 465 466 467 468 469 470 471 472 473 474 475 476 477 478 479 480 481 482 483 484 485 486 487 488 489 490 491 492 493 494 495 496 497 498 499 500 501 502 503 504 505 506 507 508 509 510 511 512 513 514 515 516 517 518 519 520 521 522 523 524 525 526 527 528 529 530 531 532 533 534 535 536 537 538 539 540 541 542 543 544 545 546 547 548 549 550 551 552 553 554 555 556 557 558 559 560 561 562 563 564 565 566 567 568 569 570 571 572 573 574 575 576 577 578 579 580 581 582 583 584 585 586 587 588 589 590 591 592 593 594 595 596 597 598 599 600 601 602 603 604 605 606 607 608 609 610 611 612 613 614 615 616 617 618 619 620 621 622 623 624 625 626 627 628 629 630 631 632 633 634 635 636 637 638 639 640 641 642 643 644 645 646 647 648 649 650 651 652 653 654 655 656 657 658 659 660 661 662 663 664 665 666 667 668 669 670 671 672 673 674 675 676 677 678 679 680 681 682 683 684 685 686 687 688 689 690 691 692 693 694 695 696 697 698 699 700 701 702 703 704 705 706 707 708 709 710 711 712 713 714 715 716 717 718 719 720 721 722 723 724 725 726 727 728 729 730 731 732 733 734 735 736 737 738 739 740 741 742 743 744 745 746 747 748 749 750 751 752 753 754 755 756 757 758 759 760 761 762 763 764 765 766 767 768 769 770 771 772 773 774 775 776 777 778 779 780 781 782 783 784 785 786 787 788 789 790 791 792 793 794 795 796 797 798 799 800 801 802 803 804 805 806 807 808 809 810 811 812 813 814 815 816 817 818 819 820 821 822 823 824 825 826 827 828 829 830 831 832 833 834 835 836 837 838 839 840 841 842 843 844 845 846 847 848 849 850 851 852 853 854 855 856 857 858 859 860 861 862 863 864 865 866 867 868 869 870 871 872 873 874 875 876 877 878 879 880 881 882 883 884 885 886 887 888 889 890 891 892 893 894 895 896 897 898 899 900 901 902 903 904 905 906 907 908 909 910 911 912 913 914 915 916 917 918 919 920 921 922 923 924 925 926 927 928 929 930 931 932 933 934 935 936 937 938 939 940 941 942 943 944 945 946 947 948 949 950 951 952 953 954 955 956 957 958 959 960 961 962 963 964 965 966 967 968 969 970 971 972 973 974 975 976 977 978 979 980 981 982 983 984 985 986 987 988 989 990 991 992 993 994 995 996 997 998 999 1000 1001 1002 1003 1004 1005 1006 1007 1008 1009 1010 1011 1012 1013 1014 1015 1016 1017 1018 1019 1020 1021 1022 1023 1024 1025 1026 1027 1028 1029 1030 1031 1032 1033 1034 1035 1036 1037 1038 1039 1040 1041 1042 1043 1044 1045 1046 1047 1048 1049 1050 1051 1052 1053 1054 1055 1056 1057 1058 1059 1060 1061 1062 1063 1064 1065 1066 1067 1068 1069 1070 1071 1072 1073 1074 1075 1076 1077 1078 1079 1080 1081 1082 1083 1084 1085 1086 1087 1088 1089 1090 1091 1092 1093 1094 1095 1096 1097 1098 1099 1100 1101 1102 1103 1104 1105 1106 1107 1108 1109 1110 1111 1112 1113 1114 1115 1116 1117 1118 1119 1120 1121 1122 1123 1124 1125 1126 1127 1128 1129 1130 1131 1132 1133 1134 1135 1136 1137 1138 1139 1140 1141 1142 1143 1144 1145 1146 1147 1148 1149 1150 1151 1152 1153 1154 1155 1156 1157 1158 1159 1160 1161 1162 1163 1164 1165 1166 1167 1168 1169 1170 1171 1172 1173 1174 1175 1176 1177 1178 1179 1180 1181 1182 1183 1184 1185 1186 1187 1188 1189 1190 1191 1192 1193 1194 1195 1196 1197 1198 1199 1200 1201 1202 1203 1204 1205 1206 1207 1208 1209 1210 1211 1212 1213 1214 1215 1216 1217 1218 1219 1220 1221 1222 1223 1224 1225 1226 1227 1228 1229 1230 1231 1232 1233 1234 1235 1236 1237 1238 1239 1240 1241 1242 1243 1244 1245 1246 1247 1248 1249 1250 1251 1252 1253 1254 1255 1256 1257 1258 1259 1260 1261 1262 1263 1264 1265 1266 1267 1268 1269 1270 1271 1272 1273 1274 1275 1276 1277 1278 1279 1280 1281 1282 1283 1284 1285 1286 1287 1288 1289 1290 1291 1292 1293 1294 1295 1296 1297 1298 1299 1300 1301 1302 1303 1304 1305 1306 1307 1308 1309 1310 1311 1312 1313 1314 1315 1316 1317 1318 1319 1320 1321 1322 1323 1324 1325 1326 1327 1328 1329 1330 1331 1332 1333 1334 1335 1336 1337 1338 1339 1340 1341 1342 1343 1344 1345 1346 1347 1348 1349 1350 1351 1352 1353 1354 1355 1356 1357 1358 1359 1360 1361 1362 1363 1364 1365 1366 1367 1368 1369 1370 1371 1372 1373 1374 1375 1376 1377 1378 1379 1380 1381 1382 1383 1384 1385 1386 1387 1388 1389 1390 1391 1392 1393 1394 1395 1396 1397 1398 1399 1400 1401 1402 1403 1404 1405 1406 1407 1408 1409 1410 1411 1412 1413 1414 1415 1416 1417 1418 1419 1420 1421 1422 1423 1424 1425 1426 1427 1428 1429 1430 1431 1432 1433 1434 1435 1436 1437 1438 1439 1440 1441 1442 1443 1444 1445 1446 1447 1448 1449 1450 1451 1452 1453 1454 1455 1456 1457 1458 1459 1460 1461 1462 1463 1464 1465 1466 1467 1468 1469 1470 1471 1472 1473 1474 1475 1476 1477 1478 1479 1480 1481 1482 1483 1484 1485 1486 1487 1488 1489 1490 1491 1492 1493 1494 1495 1496 1497 1498 1499 1500 1501 1502 1503 1504 1505 1506 1507 1508 1509 1510 1511 1512 1513 1514 1515 1516 1517 1518 1519 1520 1521 1522 1523 1524 1525 1526 1527 1528 1529 1530 1531 1532 1533 1534 1535 1536 1537 1538 1539 1540 1541 1542 1543 1544 1545 1546 1547 1548 1549 1550 1551 1552 1553 1554 1555 1556 1557 1558 1559 1560 1561 1562 1563 1564 1565 1566 1567 1568 1569 1570 1571 1572 1573 1574 1575 1576 1577 1578 1579 1580 1581 1582 1583 1584 1585 1586 1587 1588 1589 1590 1591 1592 1593 1594 1595 1596 1597 1598 1599 1600 1601 1602 1603 1604 1605 1606 1607 1608 1609 1610 1611 1612 1613 1614 1615 1616 1617 1618 1619 1620 1621 1622 1623 1624 1625 1626 1627 1628 1629 1630 1631 1632 1633 1634 1635 1636 1637 1638 1639 1640 1641 1642 1643 1644 1645 1646 1647 1648 1649 1650 1651 1652 1653 1654 1655 1656 1657 1658 1659 1660 1661 1662 1663 1664 1665 1666 1667 1668 1669 1670 1671 1672 1673 1674 1675 1676 1677 1678 1679 1680 1681 1682 1683 1684 1685 1686 1687 1688 1689 1690 1691 1692 1693 1694 1695 1696 1697 1698 1699 1700 1701 1702 1703 1704 1705 1706 1707 1708 1709 1710 1711 1712 1713 1714 1715 1716 1717 1718 1719 1720 1721 1722 1723 1724 1725 1726 1727 1728 1729 1730 1731 1732 1733 1734 1735 1736 1737 1738 1739 1740 1741 1742 1743 1744 1745 1746 1747 1748 1749 1750 1751 1752 1753 1754 1755 1756 1757 1758 1759 1760 1761 1762 1763 1764 1765 1766 1767 1768 1769 1770 1771 1772 1773 1774 1775 1776 1777 1778 1779 1780 1781 1782 1783 1784 1785 1786 1787 1788 1789 1790 1791 1792 1793 1794 1795 1796 1797 1798 1799 1800 1801 1802 1803 1804 1805 1806 1807 1808 1809 1810 1811 1812 1813 1814 1815 1816 1817 1818 1819 1820 1821 1822 1823 1824 1825 1826 1827 1828 1829 1830 1831 1832 1833 1834 1835 1836 1837 1838 1839 1840 1841 1842 1843 1844 1845 1846 1847 1848 1849 1850 1851 1852 1853 1854 1855 1856 1857 1858 1859 1860 1861 1862 1863 1864 1865 1866 1867 1868 1869 1870 1871 1872 1873 1874 1875 1876 1877 1878 1879 1880 1881 1882 1883 1884 1885 1886 1887 1888 1889 1890 1891 1892 1893 1894 1895 1896 1897 1898 1899 1900 1901 1902 1903 1904 1905 1906 1907 1908 1909 1910 1911 1912 1913 1914 1915 1916 1917 1918 1919 1920 1921 1922 1923 1924 1925 1926 1927 1928 1929 1930 1931 1932 1933 1934 1935 1936 1937 1938 1939 1940 1941 1942 1943 1944 1945 1946 1947 1948 1949 1950 1951 1952 1953 1954 1955 1956 1957 1958 1959 1960 1961 1962 1963 1964 1965 1966 1967 1968 1969 1970 1971 1972 1973 1974 1975 1976 1977 1978 1979 1980 1981 1982 1983 1984 1985 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 2034 2035 2036 2037 2038 2039 2040 2041 2042 2043 2044 2045 2046 2047 2048 2049 2050 2051 2052 2053 2054 2055 2056 2057 2058 2059 2060 2061 2062 2063 2064 2065 2066 2067 2068 2069 2070 2071 2072 2073 2074 2075 2076 2077 2078 2079 2080 2081 2082 2083 2084 2085 2086 2087 2088 2089 2090 2091 2092 2093 2094 2095 2096 2097 2098 2099 2100 2101 2102 2103 2104 2105 2106 2107 2108 2109 2110 2111 2112 2113 2114 2115 2116 2117 2118 2119 2120 2121 2122 2123 2124 2125 2126 2127 2128 2129 2130 2131 2132 2133 2134 2135 2136 2137 2138 2139 2140 2141 2142 2143 2144 2145 2146 2147 2148 2149 2150 2151 2152 2153 2154 2155 2156 2157 2158 2159 2160 2161 2162 2163 2164 2165 2166 2167 2168 2169 2170 2171 2172 2173 2174 2175 2176 2177 2178 2179 2180 2181 2182 2183 2184 2185 2186 2187 2188 2189 2190 2191 2192 2193 2194 2195 2196 2197 2198 2199 2200 2201 2202 2203 2204 2205 2206 2207 2208 2209 2210 2211 2212 2213 2214 2215 2216 2217 2218 2219 2220 2221 2222 2223 2224 2225 2226 2227 2228 2229 2230 2231 2232 2233 2234 2235 2236 2237 2238 2239 2240 2241 2242 2243 2244 2245 2246 2247 2248 2249 2250 2251 2252 2253 2254 2255 2256 2257 2258 2259 2260 2261 2262 2263 2264 2265 2266 2267 2268 2269 2270 2271 2272 2273 2274 2275 2276 2277 2278 2279 2280 2281 2282 2283 2284 2285 2286 2287 2288 2289 2290 2291 2292 2293 2294 2295 2296 2297 2298 2299 2300 2301 2302 2303 2304 2305 2306 2307 2308 2309 2310 2311 2312 2313 2314 2315 2316 2317 2318 2319 2320 2321 2322 2323 2324 2325 2326 2327 2328 2329 2330 2331 2332 2333 2334 2335 2336 2337 2338 2339 2340 2341 2342 2343 2344 2345 2346 2347 2348 2349 2350 2351 2352 2353 2354 2355 2356 2357 2358 2359 2360 2361 2362 2363 2364 2365 2366 2367 2368 2369 |
{
"cells": [
{
"cell_type": "code",
"execution_count": 86,
"metadata": {},
"outputs": [],
"source": [
"from sentence_transformers import SentenceTransformer, util\n",
"import pandas as pd\n",
"import re"
]
},
{
"cell_type": "code",
"execution_count": 87,
"metadata": {},
"outputs": [],
"source": [
"# Target列を分割する関数\n",
"def split_target(target):\n",
" # 指定された区切り文字で分割\n",
" split_words = re.split(r'[,\\n、・及びおよび又はまたは]+', target)\n",
" # 空白文字を除外してリストとして返す\n",
" return [word.strip() for word in split_words if word.strip()]"
]
},
{
"cell_type": "code",
"execution_count": 88,
"metadata": {},
"outputs": [],
"source": [
"basedf = pd.read_csv('../ClinicalTrialCSV/JRCT20241202Cancer.csv', index_col=0)\n",
"basedf = basedf.dropna(subset=['試験等のフェーズ'])\n",
"# Target列を分割してTargetWord列を追加\n",
"basedf['TargetWord'] = basedf['Target'].apply(split_target)"
]
},
{
"cell_type": "code",
"execution_count": 84,
"metadata": {},
"outputs": [
{
"data": {
"text/html": [
"<div>\n",
"<style scoped>\n",
" .dataframe tbody tr th:only-of-type {\n",
" vertical-align: middle;\n",
" }\n",
"\n",
" .dataframe tbody tr th {\n",
" vertical-align: top;\n",
" }\n",
"\n",
" .dataframe thead th {\n",
" text-align: right;\n",
" }\n",
"</style>\n",
"<table border=\"1\" class=\"dataframe\">\n",
" <thead>\n",
" <tr style=\"text-align: right;\">\n",
" <th></th>\n",
" <th>JRCT ID</th>\n",
" <th>NCT No</th>\n",
" <th>JapicCTI No</th>\n",
" <th>Title</th>\n",
" <th>Target</th>\n",
" <th>研究・治験の目的</th>\n",
" <th>試験等のフェーズ</th>\n",
" <th>試験の種類</th>\n",
" <th>無作為化</th>\n",
" <th>盲検化</th>\n",
" <th>...</th>\n",
" <th>purpose</th>\n",
" <th>Inclusion Criteria</th>\n",
" <th>Exclusion Criteria</th>\n",
" <th>Age Minimum</th>\n",
" <th>Age Maximum</th>\n",
" <th>Gender</th>\n",
" <th>Discontinuation Criteria</th>\n",
" <th>Keyword</th>\n",
" <th>Intervention(s)</th>\n",
" <th>TargetWord</th>\n",
" </tr>\n",
" </thead>\n",
" <tbody>\n",
" <tr>\n",
" <th>0</th>\n",
" <td>jRCT2021240039</td>\n",
" <td>NCT06632951</td>\n",
" <td>NaN</td>\n",
" <td>[M25-204]転移性尿路上皮癌患者を対象に，livmoniplimab とbudigal...</td>\n",
" <td>尿路上皮癌</td>\n",
" <td>主要目的：全生存期間（以下「OS」）を指標として，livmoniplimab と budig...</td>\n",
" <td>2</td>\n",
" <td>NaN</td>\n",
" <td>無作為化比較</td>\n",
" <td>非盲検</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>-Participant has histologically or cytological...</td>\n",
" <td>-Participant has received more than 1 prior ch...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>-Arm 1: Livmoniplimab (Dose A) + Budigalimab\\r...</td>\n",
" <td>[尿路上皮癌]</td>\n",
" </tr>\n",
" <tr>\n",
" <th>4</th>\n",
" <td>jRCT2031240512</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>フッ化ピリミジン製剤及びプラチナ製剤を含む一次治療に不応・不耐となった切除不能進行・再発胃癌...</td>\n",
" <td>切除不能進行・再発胃癌</td>\n",
" <td>フッ化ピリミジン・プラチナ系薬剤に不応・不耐の切除不能進行・再発胃癌被験者を対象として、ベバ...</td>\n",
" <td>1</td>\n",
" <td>NaN</td>\n",
" <td>無作為化比較</td>\n",
" <td>非盲検</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>1)\\tAge between 18 and 75 years.\\r\\n2)\\tPerfor...</td>\n",
" <td>1)\\tPrior treatment history with paclitaxel, r...</td>\n",
" <td>18age old over</td>\n",
" <td>75age old under</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>Safety Part (Dose Escalation):\\r\\nLevel 0: Bev...</td>\n",
" <td>[切除不能進行, 再発胃癌]</td>\n",
" </tr>\n",
" <tr>\n",
" <th>7</th>\n",
" <td>jRCT2051240197</td>\n",
" <td>NCT06692738</td>\n",
" <td>NaN</td>\n",
" <td>PD-L1 陽性の転移性扁平上皮非小細胞肺癌患者に対する一次治療として、Rilvegosto...</td>\n",
" <td>非小細胞肺癌</td>\n",
" <td>Treatment</td>\n",
" <td>3</td>\n",
" <td>NaN</td>\n",
" <td>無作為化比較</td>\n",
" <td>二重盲検</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>- Histologically or cytologically documented s...</td>\n",
" <td>- Presence of small cell and neuroendocrine hi...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>Participants will be randomized in a 1:1 ratio...</td>\n",
" <td>[非小細胞肺癌]</td>\n",
" </tr>\n",
" <tr>\n",
" <th>8</th>\n",
" <td>jRCT2031240508</td>\n",
" <td>NCT06573294</td>\n",
" <td>NaN</td>\n",
" <td>悪性固形癌患者を対象にGEN1057の安全性及び抗腫瘍活性を評価するヒト初回投与、非盲検、用...</td>\n",
" <td>進行性悪性固形癌\\n転移性悪性固形癌</td>\n",
" <td>本第I相試験の目的は、転移性又は進行性病変を有する悪性固形癌患者を対象に、GEN1057を単...</td>\n",
" <td>1</td>\n",
" <td>NaN</td>\n",
" <td>単一群</td>\n",
" <td>非盲検</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>-Advanced and/or metastatic solid tumors, who ...</td>\n",
" <td>Has been exposed to any of the following prior...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>GEN1057 monotherapy will be administered intra...</td>\n",
" <td>[進行性悪性固形癌, 転移性悪性固形癌]</td>\n",
" </tr>\n",
" <tr>\n",
" <th>12</th>\n",
" <td>jRCT2041240130</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>中等度-高度PONV発症リスクを有する肺切除術予定患者の周術期管理におけるGranisetr...</td>\n",
" <td>肺がん</td>\n",
" <td>全身麻酔を要する肺切除術周術期における標準制吐療法であるグラニセトロン(Granisetro...</td>\n",
" <td>2</td>\n",
" <td>NaN</td>\n",
" <td>無作為化比較</td>\n",
" <td>非盲検</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>(1) Patients scheduled to undergo anatomical l...</td>\n",
" <td>(1) Patients with a history of allergy to the ...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>Treatment group\\r\\nAdminister GRA 1mg intraven...</td>\n",
" <td>[肺がん]</td>\n",
" </tr>\n",
" <tr>\n",
" <th>...</th>\n",
" <td>...</td>\n",
" <td>...</td>\n",
" <td>...</td>\n",
" <td>...</td>\n",
" <td>...</td>\n",
" <td>...</td>\n",
" <td>...</td>\n",
" <td>...</td>\n",
" <td>...</td>\n",
" <td>...</td>\n",
" <td>...</td>\n",
" <td>...</td>\n",
" <td>...</td>\n",
" <td>...</td>\n",
" <td>...</td>\n",
" <td>...</td>\n",
" <td>...</td>\n",
" <td>...</td>\n",
" <td>...</td>\n",
" <td>...</td>\n",
" <td>...</td>\n",
" </tr>\n",
" <tr>\n",
" <th>974</th>\n",
" <td>jRCT2031200203</td>\n",
" <td>NCT04379596</td>\n",
" <td>NaN</td>\n",
" <td>HER2発現の成人胃癌患者を対象としてトラスツズマブ デルクステカン（T-DXd）の単剤療法...</td>\n",
" <td>胃腺癌、胃食道接合部腺癌又は食道腺癌</td>\n",
" <td>DESTINY-Gastric03は、HER2発現の進行・転移性胃癌・胃食道接合部（GEJ）...</td>\n",
" <td>1-2</td>\n",
" <td>NaN</td>\n",
" <td>無作為化比較</td>\n",
" <td>非盲検</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>1. Male and female participants must be at lea...</td>\n",
" <td>1. History of active primary immunodeficiency,...</td>\n",
" <td>18age old over</td>\n",
" <td>130age old under</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>Experimental: Arm 1A: T-DXd and 5-fluorouracil...</td>\n",
" <td>[胃腺癌, 胃食道接合部腺癌, 食道腺癌]</td>\n",
" </tr>\n",
" <tr>\n",
" <th>981</th>\n",
" <td>jRCT2031200153</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>Cellm-001による初発膠芽腫治療効果無作為比較対照試験</td>\n",
" <td>膠芽腫</td>\n",
" <td>脳腫瘍のうち、初発悪性膠芽腫に対する自家脳腫瘍免疫賦活剤であるCellm-001について、術...</td>\n",
" <td>3</td>\n",
" <td>NaN</td>\n",
" <td>無作為化比較</td>\n",
" <td>二重盲検</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>(1) 18 years old or older and 75 years old or ...</td>\n",
" <td>(1) Systemic administration of corticosteroids...</td>\n",
" <td>18age old over</td>\n",
" <td>75age old under</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>Inject the investigational drug (Cellm-001 or ...</td>\n",
" <td>[膠芽腫]</td>\n",
" </tr>\n",
" <tr>\n",
" <th>996</th>\n",
" <td>jRCT2031200087</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>4型進行胃癌に対する術後または周術期補助化学療法としての全身・腹腔内併用化学療法と全身化学療...</td>\n",
" <td>4型進行胃癌</td>\n",
" <td>術後腹膜播種のリスクが高い4型進行胃癌を対象として、全身・腹腔内併用化学療法の全身化学療法に...</td>\n",
" <td>3</td>\n",
" <td>NaN</td>\n",
" <td>無作為化比較</td>\n",
" <td>非盲検</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>Confirmation before temporary registration\\r\\n...</td>\n",
" <td>1)\\tSimultaneously active double cancer.\\r\\n2)...</td>\n",
" <td>20age old over</td>\n",
" <td>75age old under</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>S-1 monotherapy\\r\\noral S-1 80 mg/m2/day on da...</td>\n",
" <td>[4型進行胃癌]</td>\n",
" </tr>\n",
" <tr>\n",
" <th>1053</th>\n",
" <td>jRCT2033190086</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>悪性黒色腫患者を対象としたインターロイキン12発現型遺伝子組換え単純ヘルペスウイルス１型の第...</td>\n",
" <td>悪性黒色腫</td>\n",
" <td>第Ⅰ相パート：進行期の悪性黒色腫患者を対象として、ヒトIL-12発現型遺伝子組換え単純ヘルペ...</td>\n",
" <td>1-2</td>\n",
" <td>NaN</td>\n",
" <td>単一群</td>\n",
" <td>非盲検</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>(Phase 1)\\r\\n1) Histologically confirmed malig...</td>\n",
" <td>(Phase 1 and 2)\\r\\n1) Patients who have brain ...</td>\n",
" <td>20age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>malignamt melanoma, advanced stage</td>\n",
" <td>Test drug (T-hIL12) will be administered into ...</td>\n",
" <td>[悪性黒色腫]</td>\n",
" </tr>\n",
" <tr>\n",
" <th>1067</th>\n",
" <td>jRCT2051190009</td>\n",
" <td>NCT03818893</td>\n",
" <td>JapicCTI-194618</td>\n",
" <td>進行性悪性黒色腫患者を対象としたGEN0101の皮内投与と、ペムブロリズマブ（抗PD-1抗体...</td>\n",
" <td>進行性悪性黒色腫</td>\n",
" <td>抗PD-1抗体治療でSDが確定した、またはPDとなった患者を対象とし、非盲検下でGEN010...</td>\n",
" <td>1-2</td>\n",
" <td>NaN</td>\n",
" <td>非無作為化比較</td>\n",
" <td>非盲検</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>Inclusion criteria \\r\\nPatients meeting all of...</td>\n",
" <td>Exclusion criteria\\r\\nPatients meeting any of ...</td>\n",
" <td>20age old over</td>\n",
" <td>86age old not</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>advanced melanoma</td>\n",
" <td>combination therapy of intracutaneous GEN0101 ...</td>\n",
" <td>[進行性悪性黒色腫]</td>\n",
" </tr>\n",
" </tbody>\n",
"</table>\n",
"<p>416 rows × 39 columns</p>\n",
"</div>"
],
"text/plain": [
" JRCT ID NCT No JapicCTI No \\\n",
"0 jRCT2021240039 NCT06632951 NaN \n",
"4 jRCT2031240512 NaN NaN \n",
"7 jRCT2051240197 NCT06692738 NaN \n",
"8 jRCT2031240508 NCT06573294 NaN \n",
"12 jRCT2041240130 NaN NaN \n",
"... ... ... ... \n",
"974 jRCT2031200203 NCT04379596 NaN \n",
"981 jRCT2031200153 NaN NaN \n",
"996 jRCT2031200087 NaN NaN \n",
"1053 jRCT2033190086 NaN NaN \n",
"1067 jRCT2051190009 NCT03818893 JapicCTI-194618 \n",
"\n",
" Title Target \\\n",
"0 [M25-204]転移性尿路上皮癌患者を対象に，livmoniplimab とbudigal... 尿路上皮癌 \n",
"4 フッ化ピリミジン製剤及びプラチナ製剤を含む一次治療に不応・不耐となった切除不能進行・再発胃癌... 切除不能進行・再発胃癌 \n",
"7 PD-L1 陽性の転移性扁平上皮非小細胞肺癌患者に対する一次治療として、Rilvegosto... 非小細胞肺癌 \n",
"8 悪性固形癌患者を対象にGEN1057の安全性及び抗腫瘍活性を評価するヒト初回投与、非盲検、用... 進行性悪性固形癌\\n転移性悪性固形癌 \n",
"12 中等度-高度PONV発症リスクを有する肺切除術予定患者の周術期管理におけるGranisetr... 肺がん \n",
"... ... ... \n",
"974 HER2発現の成人胃癌患者を対象としてトラスツズマブ デルクステカン（T-DXd）の単剤療法... 胃腺癌、胃食道接合部腺癌又は食道腺癌 \n",
"981 Cellm-001による初発膠芽腫治療効果無作為比較対照試験 膠芽腫 \n",
"996 4型進行胃癌に対する術後または周術期補助化学療法としての全身・腹腔内併用化学療法と全身化学療... 4型進行胃癌 \n",
"1053 悪性黒色腫患者を対象としたインターロイキン12発現型遺伝子組換え単純ヘルペスウイルス１型の第... 悪性黒色腫 \n",
"1067 進行性悪性黒色腫患者を対象としたGEN0101の皮内投与と、ペムブロリズマブ（抗PD-1抗体... 進行性悪性黒色腫 \n",
"\n",
" 研究・治験の目的 試験等のフェーズ 試験の種類 \\\n",
"0 主要目的：全生存期間（以下「OS」）を指標として，livmoniplimab と budig... 2 NaN \n",
"4 フッ化ピリミジン・プラチナ系薬剤に不応・不耐の切除不能進行・再発胃癌被験者を対象として、ベバ... 1 NaN \n",
"7 Treatment 3 NaN \n",
"8 本第I相試験の目的は、転移性又は進行性病変を有する悪性固形癌患者を対象に、GEN1057を単... 1 NaN \n",
"12 全身麻酔を要する肺切除術周術期における標準制吐療法であるグラニセトロン(Granisetro... 2 NaN \n",
"... ... ... ... \n",
"974 DESTINY-Gastric03は、HER2発現の進行・転移性胃癌・胃食道接合部（GEJ）... 1-2 NaN \n",
"981 脳腫瘍のうち、初発悪性膠芽腫に対する自家脳腫瘍免疫賦活剤であるCellm-001について、術... 3 NaN \n",
"996 術後腹膜播種のリスクが高い4型進行胃癌を対象として、全身・腹腔内併用化学療法の全身化学療法に... 3 NaN \n",
"1053 第Ⅰ相パート：進行期の悪性黒色腫患者を対象として、ヒトIL-12発現型遺伝子組換え単純ヘルペ... 1-2 NaN \n",
"1067 抗PD-1抗体治療でSDが確定した、またはPDとなった患者を対象とし、非盲検下でGEN010... 1-2 NaN \n",
"\n",
" 無作為化 盲検化 ... purpose \\\n",
"0 無作為化比較 非盲検 ... treatment purpose \n",
"4 無作為化比較 非盲検 ... treatment purpose \n",
"7 無作為化比較 二重盲検 ... treatment purpose \n",
"8 単一群 非盲検 ... treatment purpose \n",
"12 無作為化比較 非盲検 ... treatment purpose \n",
"... ... ... ... ... \n",
"974 無作為化比較 非盲検 ... treatment purpose \n",
"981 無作為化比較 二重盲検 ... treatment purpose \n",
"996 無作為化比較 非盲検 ... treatment purpose \n",
"1053 単一群 非盲検 ... treatment purpose \n",
"1067 非無作為化比較 非盲検 ... treatment purpose \n",
"\n",
" Inclusion Criteria \\\n",
"0 -Participant has histologically or cytological... \n",
"4 1)\\tAge between 18 and 75 years.\\r\\n2)\\tPerfor... \n",
"7 - Histologically or cytologically documented s... \n",
"8 -Advanced and/or metastatic solid tumors, who ... \n",
"12 (1) Patients scheduled to undergo anatomical l... \n",
"... ... \n",
"974 1. Male and female participants must be at lea... \n",
"981 (1) 18 years old or older and 75 years old or ... \n",
"996 Confirmation before temporary registration\\r\\n... \n",
"1053 (Phase 1)\\r\\n1) Histologically confirmed malig... \n",
"1067 Inclusion criteria \\r\\nPatients meeting all of... \n",
"\n",
" Exclusion Criteria Age Minimum \\\n",
"0 -Participant has received more than 1 prior ch... 18age old over \n",
"4 1)\\tPrior treatment history with paclitaxel, r... 18age old over \n",
"7 - Presence of small cell and neuroendocrine hi... 18age old over \n",
"8 Has been exposed to any of the following prior... 18age old over \n",
"12 (1) Patients with a history of allergy to the ... 18age old over \n",
"... ... ... \n",
"974 1. History of active primary immunodeficiency,... 18age old over \n",
"981 (1) Systemic administration of corticosteroids... 18age old over \n",
"996 1)\\tSimultaneously active double cancer.\\r\\n2)... 20age old over \n",
"1053 (Phase 1 and 2)\\r\\n1) Patients who have brain ... 20age old over \n",
"1067 Exclusion criteria\\r\\nPatients meeting any of ... 20age old over \n",
"\n",
" Age Maximum Gender Discontinuation Criteria \\\n",
"0 No limit Both NaN \n",
"4 75age old under Both NaN \n",
"7 No limit Both NaN \n",
"8 No limit Both NaN \n",
"12 No limit Both NaN \n",
"... ... ... ... \n",
"974 130age old under Both NaN \n",
"981 75age old under Both NaN \n",
"996 75age old under Both NaN \n",
"1053 No limit Both NaN \n",
"1067 86age old not Both NaN \n",
"\n",
" Keyword \\\n",
"0 NaN \n",
"4 NaN \n",
"7 NaN \n",
"8 NaN \n",
"12 NaN \n",
"... ... \n",
"974 NaN \n",
"981 NaN \n",
"996 NaN \n",
"1053 malignamt melanoma, advanced stage \n",
"1067 advanced melanoma \n",
"\n",
" Intervention(s) TargetWord \n",
"0 -Arm 1: Livmoniplimab (Dose A) + Budigalimab\\r... [尿路上皮癌] \n",
"4 Safety Part (Dose Escalation):\\r\\nLevel 0: Bev... [切除不能進行, 再発胃癌] \n",
"7 Participants will be randomized in a 1:1 ratio... [非小細胞肺癌] \n",
"8 GEN1057 monotherapy will be administered intra... [進行性悪性固形癌, 転移性悪性固形癌] \n",
"12 Treatment group\\r\\nAdminister GRA 1mg intraven... [肺がん] \n",
"... ... ... \n",
"974 Experimental: Arm 1A: T-DXd and 5-fluorouracil... [胃腺癌, 胃食道接合部腺癌, 食道腺癌] \n",
"981 Inject the investigational drug (Cellm-001 or ... [膠芽腫] \n",
"996 S-1 monotherapy\\r\\noral S-1 80 mg/m2/day on da... [4型進行胃癌] \n",
"1053 Test drug (T-hIL12) will be administered into ... [悪性黒色腫] \n",
"1067 combination therapy of intracutaneous GEN0101 ... [進行性悪性黒色腫] \n",
"\n",
"[416 rows x 39 columns]"
]
},
"execution_count": 84,
"metadata": {},
"output_type": "execute_result"
}
],
"source": [
"basedf"
]
},
{
"cell_type": "code",
"execution_count": 89,
"metadata": {},
"outputs": [
{
"name": "stderr",
"output_type": "stream",
"text": [
"/Users/satoc/miniforge3/envs/gradio/lib/python3.12/site-packages/transformers/tokenization_utils_base.py:1617: FutureWarning: `clean_up_tokenization_spaces` was not set. It will be set to `True` by default. This behavior will be deprecated in transformers v4.45, and will be then set to `False` by default. For more details check this issue: https://github.com/huggingface/transformers/issues/31884\n",
" warnings.warn(\n"
]
}
],
"source": [
"# クエリ\n",
"query = \"乳がん\"\n",
"\n",
"# モデルのロード\n",
"model = SentenceTransformer('all-MiniLM-L6-v2')\n",
"\n",
"# クエリをベクトル化\n",
"query_vec = model.encode(query, convert_to_tensor=True)\n"
]
},
{
"cell_type": "code",
"execution_count": 102,
"metadata": {},
"outputs": [],
"source": [
"# ターゲットリスト全体を処理\n",
"matched_indices = []\n",
"target_vecs_list = []\n",
"cosine_scores_list = []\n",
"for idx, target_words in enumerate(basedf['TargetWord']):\n",
" # ターゲット内の各単語をベクトル化\n",
" target_vecs = model.encode(target_words, convert_to_tensor=True)\n",
" # コサイン類似度を計算\n",
" cosine_scores = util.cos_sim(query_vec, target_vecs).squeeze()\n",
" target_vecs_list.append(target_vecs)\n",
" cosine_scores_list.append(cosine_scores)\n",
" # 閾値を超えるか確認\n",
" if (cosine_scores >= 0.7).any(): # いずれかが閾値を超えている場合\n",
" matched_indices.append(idx)\n",
"\n",
"# 抽出\n",
"matched_df = basedf.iloc[matched_indices]"
]
},
{
"cell_type": "code",
"execution_count": 113,
"metadata": {},
"outputs": [
{
"data": {
"text/plain": [
"4"
]
},
"execution_count": 113,
"metadata": {},
"output_type": "execute_result"
}
],
"source": [
"matched_indices[0]"
]
},
{
"cell_type": "code",
"execution_count": 115,
"metadata": {},
"outputs": [
{
"name": "stdout",
"output_type": "stream",
"text": [
"tensor(1., device='mps:0')\n",
"tensor([0.5316, 0.7820, 0.9005, 0.6651, 0.6537], device='mps:0')\n",
"tensor(0.7820, device='mps:0')\n",
"tensor([0.8813, 0.7659, 0.7375, 0.6654], device='mps:0')\n",
"tensor([0.4314, 0.7559], device='mps:0')\n",
"tensor(0.7012, device='mps:0')\n",
"tensor(0.9683, device='mps:0')\n",
"tensor([0.8813, 0.6887, 0.7659], device='mps:0')\n",
"tensor(0.7820, device='mps:0')\n",
"tensor(0.7820, device='mps:0')\n",
"tensor(0.7190, device='mps:0')\n",
"tensor(1., device='mps:0')\n",
"tensor([0.8813, 0.6887, 0.7659], device='mps:0')\n",
"tensor([0.5691, 0.9683], device='mps:0')\n",
"tensor([1.0000, 0.5633, 0.8272], device='mps:0')\n",
"tensor(0.7820, device='mps:0')\n",
"tensor([0.4257, 0.7559], device='mps:0')\n",
"tensor([0.6060, 0.8272], device='mps:0')\n",
"tensor(0.9683, device='mps:0')\n",
"tensor(0.9683, device='mps:0')\n",
"tensor([0.4901, 0.7075], device='mps:0')\n",
"tensor(0.9683, device='mps:0')\n",
"tensor([1.0000, 0.9335], device='mps:0')\n",
"tensor(0.7103, device='mps:0')\n",
"tensor([0.6060, 0.9335], device='mps:0')\n",
"tensor([0.6060, 0.8272, 0.6060, 0.5189, 0.6060, 0.5161], device='mps:0')\n",
"tensor([0.7628, 0.4268, 0.1960], device='mps:0')\n",
"tensor([0.9683, 0.5335], device='mps:0')\n",
"tensor(0.7223, device='mps:0')\n",
"tensor([0.5981, 0.4374, 0.4223, 0.5691, 0.9683], device='mps:0')\n",
"tensor(0.9683, device='mps:0')\n",
"tensor([0.5651, 0.8813], device='mps:0')\n",
"tensor([0.9683, 0.4708, 0.5691], device='mps:0')\n",
"tensor([0.5039, 0.4994, 0.9005, 0.9683], device='mps:0')\n",
"tensor([1.0000, 0.9335], device='mps:0')\n",
"tensor(0.9683, device='mps:0')\n",
"tensor(0.9683, device='mps:0')\n",
"tensor(0.7659, device='mps:0')\n",
"tensor([0.5464, 0.8813], device='mps:0')\n",
"tensor([0.5633, 1.0000], device='mps:0')\n",
"tensor(0.9387, device='mps:0')\n",
"tensor([0.6637, 0.5138, 0.9683, 0.4046, 0.4765], device='mps:0')\n",
"tensor(0.9683, device='mps:0')\n",
"tensor(1., device='mps:0')\n",
"tensor(0.9683, device='mps:0')\n",
"tensor(0.9683, device='mps:0')\n",
"tensor([0.6060, 0.8272], device='mps:0')\n",
"tensor(0.9683, device='mps:0')\n",
"tensor([0.5651, 0.8813], device='mps:0')\n",
"tensor(1., device='mps:0')\n",
"tensor([0.7099, 0.7024], device='mps:0')\n",
"tensor(0.7820, device='mps:0')\n",
"tensor(0.8280, device='mps:0')\n",
"tensor([0.9683, 0.8464, 0.0214, 0.1548], device='mps:0')\n",
"tensor(0.9683, device='mps:0')\n"
]
}
],
"source": [
"for n in matched_indices:\n",
" print(cosine_scores_list[n])"
]
},
{
"cell_type": "code",
"execution_count": 106,
"metadata": {},
"outputs": [
{
"name": "stdout",
"output_type": "stream",
"text": [
"torch.Size([1, 384])\n",
"torch.Size([2, 384])\n",
"torch.Size([1, 384])\n",
"torch.Size([2, 384])\n",
"torch.Size([1, 384])\n",
"torch.Size([2, 384])\n",
"torch.Size([1, 384])\n",
"torch.Size([1, 384])\n",
"torch.Size([2, 384])\n",
"torch.Size([1, 384])\n",
"torch.Size([1, 384])\n",
"torch.Size([1, 384])\n",
"torch.Size([1, 384])\n",
"torch.Size([1, 384])\n",
"torch.Size([1, 384])\n",
"torch.Size([2, 384])\n",
"torch.Size([1, 384])\n",
"torch.Size([1, 384])\n",
"torch.Size([1, 384])\n",
"torch.Size([1, 384])\n",
"torch.Size([1, 384])\n",
"torch.Size([2, 384])\n",
"torch.Size([3, 384])\n",
"torch.Size([1, 384])\n",
"torch.Size([1, 384])\n",
"torch.Size([1, 384])\n",
"torch.Size([1, 384])\n",
"torch.Size([1, 384])\n",
"torch.Size([1, 384])\n",
"torch.Size([5, 384])\n",
"torch.Size([3, 384])\n",
"torch.Size([1, 384])\n",
"torch.Size([1, 384])\n",
"torch.Size([1, 384])\n",
"torch.Size([1, 384])\n",
"torch.Size([1, 384])\n",
"torch.Size([1, 384])\n",
"torch.Size([2, 384])\n",
"torch.Size([2, 384])\n",
"torch.Size([4, 384])\n",
"torch.Size([1, 384])\n",
"torch.Size([4, 384])\n",
"torch.Size([3, 384])\n",
"torch.Size([2, 384])\n",
"torch.Size([1, 384])\n",
"torch.Size([1, 384])\n",
"torch.Size([2, 384])\n",
"torch.Size([1, 384])\n",
"torch.Size([1, 384])\n",
"torch.Size([1, 384])\n",
"torch.Size([1, 384])\n",
"torch.Size([1, 384])\n",
"torch.Size([1, 384])\n",
"torch.Size([3, 384])\n",
"torch.Size([1, 384])\n",
"torch.Size([1, 384])\n",
"torch.Size([4, 384])\n",
"torch.Size([1, 384])\n",
"torch.Size([2, 384])\n",
"torch.Size([1, 384])\n",
"torch.Size([1, 384])\n",
"torch.Size([4, 384])\n",
"torch.Size([1, 384])\n",
"torch.Size([1, 384])\n",
"torch.Size([1, 384])\n",
"torch.Size([1, 384])\n",
"torch.Size([2, 384])\n",
"torch.Size([1, 384])\n",
"torch.Size([1, 384])\n",
"torch.Size([1, 384])\n",
"torch.Size([1, 384])\n",
"torch.Size([1, 384])\n",
"torch.Size([1, 384])\n",
"torch.Size([5, 384])\n",
"torch.Size([1, 384])\n",
"torch.Size([1, 384])\n",
"torch.Size([2, 384])\n",
"torch.Size([1, 384])\n",
"torch.Size([1, 384])\n",
"torch.Size([1, 384])\n",
"torch.Size([1, 384])\n",
"torch.Size([1, 384])\n",
"torch.Size([1, 384])\n",
"torch.Size([3, 384])\n",
"torch.Size([4, 384])\n",
"torch.Size([1, 384])\n",
"torch.Size([1, 384])\n",
"torch.Size([1, 384])\n",
"torch.Size([1, 384])\n",
"torch.Size([3, 384])\n",
"torch.Size([2, 384])\n",
"torch.Size([1, 384])\n",
"torch.Size([1, 384])\n",
"torch.Size([3, 384])\n",
"torch.Size([3, 384])\n",
"torch.Size([1, 384])\n",
"torch.Size([2, 384])\n",
"torch.Size([1, 384])\n",
"torch.Size([1, 384])\n",
"torch.Size([3, 384])\n"
]
}
],
"source": [
"for i in range(100):\n",
" print(target_vecs_list[i].shape)"
]
},
{
"cell_type": "code",
"execution_count": 108,
"metadata": {},
"outputs": [
{
"name": "stdout",
"output_type": "stream",
"text": [
"torch.Size([])\n",
"torch.Size([2])\n",
"torch.Size([])\n",
"torch.Size([2])\n",
"torch.Size([])\n",
"torch.Size([2])\n",
"torch.Size([])\n",
"torch.Size([])\n",
"torch.Size([2])\n",
"torch.Size([])\n",
"torch.Size([])\n",
"torch.Size([])\n",
"torch.Size([])\n",
"torch.Size([])\n",
"torch.Size([])\n",
"torch.Size([2])\n",
"torch.Size([])\n",
"torch.Size([])\n",
"torch.Size([])\n",
"torch.Size([])\n",
"torch.Size([])\n",
"torch.Size([2])\n",
"torch.Size([3])\n",
"torch.Size([])\n",
"torch.Size([])\n",
"torch.Size([])\n",
"torch.Size([])\n",
"torch.Size([])\n",
"torch.Size([])\n",
"torch.Size([5])\n",
"torch.Size([3])\n",
"torch.Size([])\n",
"torch.Size([])\n",
"torch.Size([])\n",
"torch.Size([])\n",
"torch.Size([])\n",
"torch.Size([])\n",
"torch.Size([2])\n",
"torch.Size([2])\n",
"torch.Size([4])\n",
"torch.Size([])\n",
"torch.Size([4])\n",
"torch.Size([3])\n",
"torch.Size([2])\n",
"torch.Size([])\n",
"torch.Size([])\n",
"torch.Size([2])\n",
"torch.Size([])\n",
"torch.Size([])\n",
"torch.Size([])\n",
"torch.Size([])\n",
"torch.Size([])\n",
"torch.Size([])\n",
"torch.Size([3])\n",
"torch.Size([])\n",
"torch.Size([])\n",
"torch.Size([4])\n",
"torch.Size([])\n",
"torch.Size([2])\n",
"torch.Size([])\n",
"torch.Size([])\n",
"torch.Size([4])\n",
"torch.Size([])\n",
"torch.Size([])\n",
"torch.Size([])\n",
"torch.Size([])\n",
"torch.Size([2])\n",
"torch.Size([])\n",
"torch.Size([])\n",
"torch.Size([])\n",
"torch.Size([])\n",
"torch.Size([])\n",
"torch.Size([])\n",
"torch.Size([5])\n",
"torch.Size([])\n",
"torch.Size([])\n",
"torch.Size([2])\n",
"torch.Size([])\n",
"torch.Size([])\n",
"torch.Size([])\n",
"torch.Size([])\n",
"torch.Size([])\n",
"torch.Size([])\n",
"torch.Size([3])\n",
"torch.Size([4])\n",
"torch.Size([])\n",
"torch.Size([])\n",
"torch.Size([])\n",
"torch.Size([])\n",
"torch.Size([3])\n",
"torch.Size([2])\n",
"torch.Size([])\n",
"torch.Size([])\n",
"torch.Size([3])\n",
"torch.Size([3])\n",
"torch.Size([])\n",
"torch.Size([2])\n",
"torch.Size([])\n",
"torch.Size([])\n",
"torch.Size([3])\n"
]
}
],
"source": [
"for i in range(100):\n",
" print(cosine_scores_list[i].shape)"
]
},
{
"cell_type": "code",
"execution_count": 111,
"metadata": {},
"outputs": [
{
"data": {
"text/plain": [
"tensor(0.5400, device='mps:0')"
]
},
"execution_count": 111,
"metadata": {},
"output_type": "execute_result"
}
],
"source": [
"cosine_scores_list[0]"
]
},
{
"cell_type": "code",
"execution_count": 85,
"metadata": {},
"outputs": [
{
"name": "stderr",
"output_type": "stream",
"text": [
"/Users/satoc/miniforge3/envs/gradio/lib/python3.12/site-packages/transformers/tokenization_utils_base.py:1617: FutureWarning: `clean_up_tokenization_spaces` was not set. It will be set to `True` by default. This behavior will be deprecated in transformers v4.45, and will be then set to `False` by default. For more details check this issue: https://github.com/huggingface/transformers/issues/31884\n",
" warnings.warn(\n"
]
}
],
"source": [
"# 日本語対応マルチリンガルモデルを使用(例: 'distiluse-base-multilingual-cased-v1')\n",
"model_name = 'sentence-transformers/distiluse-base-multilingual-cased-v1'\n",
"model = SentenceTransformer(model_name)"
]
},
{
"cell_type": "code",
"execution_count": 50,
"metadata": {},
"outputs": [],
"source": [
"# クエリ例\n",
"query = \"神経膠腫\"\n",
"# クエリのベクトル化\n",
"query_vec = model.encode(query, convert_to_tensor=True)\n",
"\n",
"# 全データのターゲット列をベクトル化\n",
"target_list = basedf['Target'].tolist()\n",
"target_vecs = model.encode(target_list, convert_to_tensor=True)"
]
},
{
"cell_type": "code",
"execution_count": 51,
"metadata": {},
"outputs": [],
"source": [
"# コサイン類似度を計算\n",
"cosine_scores = util.cos_sim(query_vec, target_vecs).squeeze()"
]
},
{
"cell_type": "code",
"execution_count": 56,
"metadata": {},
"outputs": [],
"source": [
"threshold = 0.7\n",
"# nonzero()の返り値はタプル (indices_array, ) なので [0] でインデックス配列を取得\n",
"matched_indices = (cosine_scores >= threshold).nonzero().tolist()\n",
"# 入れ子リストをフラットなリストに変換\n",
"flat_indices = [idx[0] for idx in matched_indices]\n",
"\n",
"# 抽出\n",
"matched_df = basedf.iloc[flat_indices]\n"
]
},
{
"cell_type": "markdown",
"metadata": {},
"source": []
},
{
"cell_type": "code",
"execution_count": 57,
"metadata": {},
"outputs": [
{
"data": {
"text/html": [
"<div>\n",
"<style scoped>\n",
" .dataframe tbody tr th:only-of-type {\n",
" vertical-align: middle;\n",
" }\n",
"\n",
" .dataframe tbody tr th {\n",
" vertical-align: top;\n",
" }\n",
"\n",
" .dataframe thead th {\n",
" text-align: right;\n",
" }\n",
"</style>\n",
"<table border=\"1\" class=\"dataframe\">\n",
" <thead>\n",
" <tr style=\"text-align: right;\">\n",
" <th></th>\n",
" <th>JRCT ID</th>\n",
" <th>NCT No</th>\n",
" <th>JapicCTI No</th>\n",
" <th>Title</th>\n",
" <th>Target</th>\n",
" <th>研究・治験の目的</th>\n",
" <th>試験等のフェーズ</th>\n",
" <th>試験の種類</th>\n",
" <th>無作為化</th>\n",
" <th>盲検化</th>\n",
" <th>...</th>\n",
" <th>assignment</th>\n",
" <th>purpose</th>\n",
" <th>Inclusion Criteria</th>\n",
" <th>Exclusion Criteria</th>\n",
" <th>Age Minimum</th>\n",
" <th>Age Maximum</th>\n",
" <th>Gender</th>\n",
" <th>Discontinuation Criteria</th>\n",
" <th>Keyword</th>\n",
" <th>Intervention(s)</th>\n",
" </tr>\n",
" </thead>\n",
" <tbody>\n",
" <tr>\n",
" <th>67</th>\n",
" <td>jRCT2051240150</td>\n",
" <td>NCT06622941</td>\n",
" <td>NaN</td>\n",
" <td>ONO-4538-126：ラブドイド腫瘍を対象としたONO-4538 の有効性及び安全性を検...</td>\n",
" <td>ラブドイド腫瘍</td>\n",
" <td>ラブドイド腫瘍を対象としたONO-4538 の有効性及び安全性を検討する</td>\n",
" <td>2</td>\n",
" <td>NaN</td>\n",
" <td>単一群</td>\n",
" <td>非盲検</td>\n",
" <td>...</td>\n",
" <td>single assignment</td>\n",
" <td>treatment purpose</td>\n",
" <td>1. Gender: Not specified\\r\\n2. Age (at the tim...</td>\n",
" <td>1. Patients with a history of active concurren...</td>\n",
" <td>1age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>For adults, Nivolumab (recombinant) is adminis...</td>\n",
" </tr>\n",
" <tr>\n",
" <th>103</th>\n",
" <td>jRCT2051240121</td>\n",
" <td>NCT06413706</td>\n",
" <td>NaN</td>\n",
" <td>放射線療法後の悪性神経膠腫の小児および若年成人を対象に、アベマシクリブ＋テモゾロミドとテモゾ...</td>\n",
" <td>悪性神経膠腫</td>\n",
" <td>放射線療法後の悪性神経膠腫を有する小児および若年成人を対象に、アベマシクリブとテモゾロミドの...</td>\n",
" <td>2</td>\n",
" <td>NaN</td>\n",
" <td>無作為化比較</td>\n",
" <td>非盲検</td>\n",
" <td>...</td>\n",
" <td>parallel assignment</td>\n",
" <td>treatment purpose</td>\n",
" <td>Subjects required to meet all the folloiwng cr...</td>\n",
" <td>Patients who meets any of the following criter...</td>\n",
" <td>No limit</td>\n",
" <td>21age old not</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>Drug: Abemaciclib\\r\\nAdministered orally\\r\\nOt...</td>\n",
" </tr>\n",
" <tr>\n",
" <th>224</th>\n",
" <td>jRCT2031240090</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>再発悪性神経膠腫に対する治療用放射性薬剤64Cu-ATSMの有効性を検証するランダム化比較医...</td>\n",
" <td>悪性神経膠腫</td>\n",
" <td>再発・難治性悪性神経膠腫を対象として、64Cu-diacetyl-bis（N4-methyl...</td>\n",
" <td>3</td>\n",
" <td>NaN</td>\n",
" <td>無作為化比較</td>\n",
" <td>非盲検</td>\n",
" <td>...</td>\n",
" <td>parallel assignment</td>\n",
" <td>treatment purpose</td>\n",
" <td>1) Histologically diagnosed as high grade glio...</td>\n",
" <td>1) Have a history or merger of other malignanc...</td>\n",
" <td>18age old over</td>\n",
" <td>75age old under</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>glioblastoma, grade3/4 astrocytoma, grade3 oli...</td>\n",
" <td>Group A: BPC Therapy\\r\\nDepending on the patie...</td>\n",
" </tr>\n",
" <tr>\n",
" <th>286</th>\n",
" <td>jRCT2071230124</td>\n",
" <td>NCT06541665</td>\n",
" <td>NaN</td>\n",
" <td>ONO-4059-13:未治療の中枢神経系原発リンパ腫（PCNSL）を対象としたONO-40...</td>\n",
" <td>中枢神経系原発リンパ腫</td>\n",
" <td>未治療PCNSL患者を対象にONO-4059 とR-MPV 療法を併用投与したときの忍容性及...</td>\n",
" <td>1</td>\n",
" <td>NaN</td>\n",
" <td>単一群</td>\n",
" <td>非盲検</td>\n",
" <td>...</td>\n",
" <td>single assignment</td>\n",
" <td>treatment purpose</td>\n",
" <td>1. Patients diagnosed with PCNSL\\r\\n2. Patient...</td>\n",
" <td>1.Patients with intraocular PCNSL without brai...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>Concomitant administration of ONO-4059 and rit...</td>\n",
" </tr>\n",
" <tr>\n",
" <th>321</th>\n",
" <td>jRCT2071230114</td>\n",
" <td>NCT06240741</td>\n",
" <td>NaN</td>\n",
" <td>日本の神経内分泌腫瘍（NEN）患者及び健康成人を対象に[68Ga]Ga-DOTA-TATEを...</td>\n",
" <td>神経内分泌腫瘍（NEN）</td>\n",
" <td>神経内分泌腫瘍（NEN）患者及び健康成人（HV）を対象に，[68Ga]Ga-DOTA-TAT...</td>\n",
" <td>3</td>\n",
" <td>NaN</td>\n",
" <td>単一群</td>\n",
" <td>非盲検</td>\n",
" <td>...</td>\n",
" <td>single assignment</td>\n",
" <td>diagnostic purpose</td>\n",
" <td>1. Signed informed consent must be obtained pr...</td>\n",
" <td>1. Inability to complete the needed investigat...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>[68Ga]Ga-DOTA-TATE will be administered intrav...</td>\n",
" </tr>\n",
" <tr>\n",
" <th>338</th>\n",
" <td>jRCT2041230136</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>再発膠芽腫に対するTUG1を標的とした核酸医薬医師主導第I相試験</td>\n",
" <td>再発膠芽腫</td>\n",
" <td>再発膠芽腫患者を対象としてTUG1ASOを投与した場合の投与時の安全性を検討し、至適投与量を...</td>\n",
" <td>1</td>\n",
" <td>NaN</td>\n",
" <td>単一群</td>\n",
" <td>非盲検</td>\n",
" <td>...</td>\n",
" <td>single assignment</td>\n",
" <td>treatment purpose</td>\n",
" <td>(1) Patients with a histological diagnosis of ...</td>\n",
" <td>(1) Patients with extracerebral metastases.\\r\\...</td>\n",
" <td>18age old over</td>\n",
" <td>75age old under</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>Dosing frequency: 1 time /week\\r\\nDose Levels\\...</td>\n",
" </tr>\n",
" <tr>\n",
" <th>349</th>\n",
" <td>jRCT2032230554</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>初発膠芽腫に対する新型高出力中性子線源を用いた加速器BNCT装置iBNCT001及びSPM-...</td>\n",
" <td>初発膠芽腫</td>\n",
" <td>治験機器iBNCT001及び治験薬SPM-011を用いたホウ素中性子捕捉療法（BNCT）に、...</td>\n",
" <td>1</td>\n",
" <td>NaN</td>\n",
" <td>非無作為化比較</td>\n",
" <td>非盲検</td>\n",
" <td>...</td>\n",
" <td>single assignment</td>\n",
" <td>other</td>\n",
" <td>- Karnofsky Performance Status is greater than...</td>\n",
" <td>- Multiple lesions, bilateral lesions, dissemi...</td>\n",
" <td>18age old over</td>\n",
" <td>85age old under</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>boron, neutron, glioblastoma</td>\n",
" <td>- Intravenous administration of investigationa...</td>\n",
" </tr>\n",
" <tr>\n",
" <th>473</th>\n",
" <td>jRCT2051230069</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>神経膠腫患者に対するロムスチン療法とプロカルバジン、ロムスチン、ビンクリスチン併⽤療法の安全...</td>\n",
" <td>神経膠腫</td>\n",
" <td>神経膠腫患者におけるロムスチン療法とプロカルバジン、ロムスチン、ビンクリスチン併⽤療法の安全...</td>\n",
" <td>1</td>\n",
" <td>NaN</td>\n",
" <td>単一群</td>\n",
" <td>非盲検</td>\n",
" <td>...</td>\n",
" <td>single assignment</td>\n",
" <td>treatment purpose</td>\n",
" <td><Cohort 1>\\r\\n All of the following items shal...</td>\n",
" <td><Common to Cohort 1 and Cohort 2>\\r\\n1) Active...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td><cohort1>\\r\\nLomustine 130 mg/m2 orally every ...</td>\n",
" </tr>\n",
" <tr>\n",
" <th>476</th>\n",
" <td>jRCT2021230016</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>皮膚血管肉腫に対するパクリタキセルとTM5614併用の安全性・有効性を検討する第Ⅱ相医師主導治験</td>\n",
" <td>皮膚血管肉腫</td>\n",
" <td>皮膚血管肉腫のパクリタキセル単剤療法無効症例を対象にTM5614とパクリタキセルの併用時にお...</td>\n",
" <td>2</td>\n",
" <td>NaN</td>\n",
" <td>単一群</td>\n",
" <td>非盲検</td>\n",
" <td>...</td>\n",
" <td>single assignment</td>\n",
" <td>treatment purpose</td>\n",
" <td>(1) Patients who are 18 years old over (at the...</td>\n",
" <td>(1) Patients with concomitant or pre-existing ...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>(TM5614)\\r\\nTM5614 should be taken orally afte...</td>\n",
" </tr>\n",
" <tr>\n",
" <th>875</th>\n",
" <td>jRCT2031210299</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>再発悪性神経膠腫患者を対象としたDSP-0390の第1相試験</td>\n",
" <td>再発悪性神経膠腫</td>\n",
" <td>再発悪性神経膠腫患者を対象にDSP-0390を経口投与したときの安全性、薬物動態、薬力学及び...</td>\n",
" <td>1</td>\n",
" <td>NaN</td>\n",
" <td>単一群</td>\n",
" <td>非盲検</td>\n",
" <td>...</td>\n",
" <td>single assignment</td>\n",
" <td>treatment purpose</td>\n",
" <td>1.\\tEstimated life expectancy >= 3 months\\r\\n2...</td>\n",
" <td>1.\\tPrior therapy with bevacizumab or other an...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>Patients will receive DSP-0390 orally once dai...</td>\n",
" </tr>\n",
" <tr>\n",
" <th>981</th>\n",
" <td>jRCT2031200153</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>Cellm-001による初発膠芽腫治療効果無作為比較対照試験</td>\n",
" <td>膠芽腫</td>\n",
" <td>脳腫瘍のうち、初発悪性膠芽腫に対する自家脳腫瘍免疫賦活剤であるCellm-001について、術...</td>\n",
" <td>3</td>\n",
" <td>NaN</td>\n",
" <td>無作為化比較</td>\n",
" <td>二重盲検</td>\n",
" <td>...</td>\n",
" <td>parallel assignment</td>\n",
" <td>treatment purpose</td>\n",
" <td>(1) 18 years old or older and 75 years old or ...</td>\n",
" <td>(1) Systemic administration of corticosteroids...</td>\n",
" <td>18age old over</td>\n",
" <td>75age old under</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>Inject the investigational drug (Cellm-001 or ...</td>\n",
" </tr>\n",
" </tbody>\n",
"</table>\n",
"<p>11 rows × 38 columns</p>\n",
"</div>"
],
"text/plain": [
" JRCT ID NCT No JapicCTI No \\\n",
"67 jRCT2051240150 NCT06622941 NaN \n",
"103 jRCT2051240121 NCT06413706 NaN \n",
"224 jRCT2031240090 NaN NaN \n",
"286 jRCT2071230124 NCT06541665 NaN \n",
"321 jRCT2071230114 NCT06240741 NaN \n",
"338 jRCT2041230136 NaN NaN \n",
"349 jRCT2032230554 NaN NaN \n",
"473 jRCT2051230069 NaN NaN \n",
"476 jRCT2021230016 NaN NaN \n",
"875 jRCT2031210299 NaN NaN \n",
"981 jRCT2031200153 NaN NaN \n",
"\n",
" Title Target \\\n",
"67 ONO-4538-126：ラブドイド腫瘍を対象としたONO-4538 の有効性及び安全性を検... ラブドイド腫瘍 \n",
"103 放射線療法後の悪性神経膠腫の小児および若年成人を対象に、アベマシクリブ＋テモゾロミドとテモゾ... 悪性神経膠腫 \n",
"224 再発悪性神経膠腫に対する治療用放射性薬剤64Cu-ATSMの有効性を検証するランダム化比較医... 悪性神経膠腫 \n",
"286 ONO-4059-13:未治療の中枢神経系原発リンパ腫（PCNSL）を対象としたONO-40... 中枢神経系原発リンパ腫 \n",
"321 日本の神経内分泌腫瘍（NEN）患者及び健康成人を対象に[68Ga]Ga-DOTA-TATEを... 神経内分泌腫瘍（NEN） \n",
"338 再発膠芽腫に対するTUG1を標的とした核酸医薬医師主導第I相試験 再発膠芽腫 \n",
"349 初発膠芽腫に対する新型高出力中性子線源を用いた加速器BNCT装置iBNCT001及びSPM-... 初発膠芽腫 \n",
"473 神経膠腫患者に対するロムスチン療法とプロカルバジン、ロムスチン、ビンクリスチン併⽤療法の安全... 神経膠腫 \n",
"476 皮膚血管肉腫に対するパクリタキセルとTM5614併用の安全性・有効性を検討する第Ⅱ相医師主導治験 皮膚血管肉腫 \n",
"875 再発悪性神経膠腫患者を対象としたDSP-0390の第1相試験 再発悪性神経膠腫 \n",
"981 Cellm-001による初発膠芽腫治療効果無作為比較対照試験 膠芽腫 \n",
"\n",
" 研究・治験の目的 試験等のフェーズ 試験の種類 \\\n",
"67 ラブドイド腫瘍を対象としたONO-4538 の有効性及び安全性を検討する 2 NaN \n",
"103 放射線療法後の悪性神経膠腫を有する小児および若年成人を対象に、アベマシクリブとテモゾロミドの... 2 NaN \n",
"224 再発・難治性悪性神経膠腫を対象として、64Cu-diacetyl-bis（N4-methyl... 3 NaN \n",
"286 未治療PCNSL患者を対象にONO-4059 とR-MPV 療法を併用投与したときの忍容性及... 1 NaN \n",
"321 神経内分泌腫瘍（NEN）患者及び健康成人（HV）を対象に，[68Ga]Ga-DOTA-TAT... 3 NaN \n",
"338 再発膠芽腫患者を対象としてTUG1ASOを投与した場合の投与時の安全性を検討し、至適投与量を... 1 NaN \n",
"349 治験機器iBNCT001及び治験薬SPM-011を用いたホウ素中性子捕捉療法（BNCT）に、... 1 NaN \n",
"473 神経膠腫患者におけるロムスチン療法とプロカルバジン、ロムスチン、ビンクリスチン併⽤療法の安全... 1 NaN \n",
"476 皮膚血管肉腫のパクリタキセル単剤療法無効症例を対象にTM5614とパクリタキセルの併用時にお... 2 NaN \n",
"875 再発悪性神経膠腫患者を対象にDSP-0390を経口投与したときの安全性、薬物動態、薬力学及び... 1 NaN \n",
"981 脳腫瘍のうち、初発悪性膠芽腫に対する自家脳腫瘍免疫賦活剤であるCellm-001について、術... 3 NaN \n",
"\n",
" 無作為化 盲検化 ... assignment purpose \\\n",
"67 単一群 非盲検 ... single assignment treatment purpose \n",
"103 無作為化比較 非盲検 ... parallel assignment treatment purpose \n",
"224 無作為化比較 非盲検 ... parallel assignment treatment purpose \n",
"286 単一群 非盲検 ... single assignment treatment purpose \n",
"321 単一群 非盲検 ... single assignment diagnostic purpose \n",
"338 単一群 非盲検 ... single assignment treatment purpose \n",
"349 非無作為化比較 非盲検 ... single assignment other \n",
"473 単一群 非盲検 ... single assignment treatment purpose \n",
"476 単一群 非盲検 ... single assignment treatment purpose \n",
"875 単一群 非盲検 ... single assignment treatment purpose \n",
"981 無作為化比較 二重盲検 ... parallel assignment treatment purpose \n",
"\n",
" Inclusion Criteria \\\n",
"67 1. Gender: Not specified\\r\\n2. Age (at the tim... \n",
"103 Subjects required to meet all the folloiwng cr... \n",
"224 1) Histologically diagnosed as high grade glio... \n",
"286 1. Patients diagnosed with PCNSL\\r\\n2. Patient... \n",
"321 1. Signed informed consent must be obtained pr... \n",
"338 (1) Patients with a histological diagnosis of ... \n",
"349 - Karnofsky Performance Status is greater than... \n",
"473 <Cohort 1>\\r\\n All of the following items shal... \n",
"476 (1) Patients who are 18 years old over (at the... \n",
"875 1.\\tEstimated life expectancy >= 3 months\\r\\n2... \n",
"981 (1) 18 years old or older and 75 years old or ... \n",
"\n",
" Exclusion Criteria Age Minimum \\\n",
"67 1. Patients with a history of active concurren... 1age old over \n",
"103 Patients who meets any of the following criter... No limit \n",
"224 1) Have a history or merger of other malignanc... 18age old over \n",
"286 1.Patients with intraocular PCNSL without brai... 18age old over \n",
"321 1. Inability to complete the needed investigat... 18age old over \n",
"338 (1) Patients with extracerebral metastases.\\r\\... 18age old over \n",
"349 - Multiple lesions, bilateral lesions, dissemi... 18age old over \n",
"473 <Common to Cohort 1 and Cohort 2>\\r\\n1) Active... 18age old over \n",
"476 (1) Patients with concomitant or pre-existing ... 18age old over \n",
"875 1.\\tPrior therapy with bevacizumab or other an... 18age old over \n",
"981 (1) Systemic administration of corticosteroids... 18age old over \n",
"\n",
" Age Maximum Gender Discontinuation Criteria \\\n",
"67 No limit Both NaN \n",
"103 21age old not NaN NaN \n",
"224 75age old under Both NaN \n",
"286 No limit Both NaN \n",
"321 No limit Both NaN \n",
"338 75age old under Both NaN \n",
"349 85age old under Both NaN \n",
"473 No limit Both NaN \n",
"476 No limit Both NaN \n",
"875 No limit Both NaN \n",
"981 75age old under Both NaN \n",
"\n",
" Keyword \\\n",
"67 NaN \n",
"103 NaN \n",
"224 glioblastoma, grade3/4 astrocytoma, grade3 oli... \n",
"286 NaN \n",
"321 NaN \n",
"338 NaN \n",
"349 boron, neutron, glioblastoma \n",
"473 NaN \n",
"476 NaN \n",
"875 NaN \n",
"981 NaN \n",
"\n",
" Intervention(s) \n",
"67 For adults, Nivolumab (recombinant) is adminis... \n",
"103 Drug: Abemaciclib\\r\\nAdministered orally\\r\\nOt... \n",
"224 Group A: BPC Therapy\\r\\nDepending on the patie... \n",
"286 Concomitant administration of ONO-4059 and rit... \n",
"321 [68Ga]Ga-DOTA-TATE will be administered intrav... \n",
"338 Dosing frequency: 1 time /week\\r\\nDose Levels\\... \n",
"349 - Intravenous administration of investigationa... \n",
"473 <cohort1>\\r\\nLomustine 130 mg/m2 orally every ... \n",
"476 (TM5614)\\r\\nTM5614 should be taken orally afte... \n",
"875 Patients will receive DSP-0390 orally once dai... \n",
"981 Inject the investigational drug (Cellm-001 or ... \n",
"\n",
"[11 rows x 38 columns]"
]
},
"execution_count": 57,
"metadata": {},
"output_type": "execute_result"
}
],
"source": [
"matched_df"
]
},
{
"cell_type": "code",
"execution_count": 58,
"metadata": {},
"outputs": [
{
"data": {
"text/plain": [
"['尿路上皮癌',\n",
" '切除不能進行・再発胃癌',\n",
" '非小細胞肺癌',\n",
" '進行性悪性固形癌\\n転移性悪性固形癌',\n",
" '肺がん',\n",
" '胃腺癌及び食道胃接合部腺癌',\n",
" '非扁平上皮非小細胞肺癌',\n",
" '未治療の濾胞性リンパ腫',\n",
" 'ミスマッチ修復機能欠損（dMMR）又は高頻度マイクロサテライト不安定性（MSI-H）を有する固形がん',\n",
" 'MET過剰発現を有する非小細胞肺癌',\n",
" '進行／転移性固形癌',\n",
" '頭頸部扁平上皮癌',\n",
" '転移性膵管腺癌（mPDAC）',\n",
" '前立腺癌',\n",
" 'トリプルネガティブ乳癌',\n",
" 'HR+/HER2-の切除不能局所進行又は転移性乳癌の患者',\n",
" '未治療の転移性非扁平上皮非小細胞肺癌（NSCLC）',\n",
" 'PD-L1陽性の転移性非小細胞肺癌',\n",
" '去勢抵抗性前立腺癌',\n",
" '切除不能皮膚血管肉腫',\n",
" 'PD-L1陽性の未治療の転移性非小細胞肺癌',\n",
" 'NSQ, NSCLC',\n",
" '卵巣癌、腹膜癌及び卵管癌',\n",
" '進行固形癌',\n",
" '進行固形癌',\n",
" '進展型小細胞肺癌',\n",
" '高リスク大細胞型B細胞リンパ腫',\n",
" '子宮体癌',\n",
" 'HER2陽性転移性乳癌',\n",
" '・進行性固形腫瘍・進行性乳がん・転移性乳がん・ホルモン受容体陽性乳がん・ホルモン受容体陽性乳がん...',\n",
" '膵管腺癌\\n非小細胞肺癌\\n大腸癌',\n",
" '進行固形がん',\n",
" '非小細胞肺癌',\n",
" 'ラブドイド腫瘍',\n",
" '非小細胞肺癌',\n",
" '膵癌',\n",
" '非ホジキンリンパ腫',\n",
" 'H3 K27M 変異を有する初発びまん性神経膠腫',\n",
" '胃癌、胃食道接合部癌',\n",
" '局所進行又は再発性の外陰癌・腟癌・子宮頸癌',\n",
" '固形癌',\n",
" '転移性固形がん\\n進行性固形がん\\n非小細胞肺がん\\nSMARCA4欠損がん',\n",
" '卵巣癌\\n子宮内膜癌\\n非小細胞肺癌',\n",
" '再発・難治性多発性骨髄腫',\n",
" '転移性去勢抵抗性前立腺癌',\n",
" 'Up-to-7基準外の中期肝細胞癌',\n",
" '進行性非小細胞肺癌（NSCLC）及びその他の固形がん',\n",
" '転移性肝臓癌',\n",
" '悪性神経膠腫',\n",
" '転移性非小細胞肺がん',\n",
" '固形がん',\n",
" '再発多形性膠芽腫',\n",
" '転移性膵管腺癌',\n",
" '転移性固形がん\\n再発性固形がん\\n進行性固形がん',\n",
" '非小細胞肺癌',\n",
" '再発性低悪性度漿液性卵巣癌（LGSOC）',\n",
" 'B細胞性非ホジキンリンパ腫\\n- 濾胞性リンパ腫(FL)\\n- びまん性大細胞型B細胞リンパ腫(DLBCL)',\n",
" '非小細胞肺癌',\n",
" '遠隔転移を伴う結腸・直腸癌',\n",
" '進行固形がん',\n",
" '肝細胞癌',\n",
" '進行又は転移例に対する標準治療による治療歴のあるKRAS G12C陽性進行又は転移性非小細胞肺癌',\n",
" '●固形腫瘍',\n",
" '進行固形がん',\n",
" '非小細胞性肺がん',\n",
" '進行性固形癌',\n",
" 'B細胞性非ホジキンリンパ腫 (NHL) \\n慢性リンパ性白血病 (CLL)',\n",
" '進行非小細胞肺がん',\n",
" 'びまん性大細胞型 B 細胞リンパ腫',\n",
" '進行固形癌',\n",
" '非小細胞肺癌',\n",
" 'HER2遺伝子異常を伴う固形腫瘍',\n",
" '固形腫瘍',\n",
" '子宮頸癌\\n胃/胃食道接合部腺癌\\nマイクロサテライト安定性結腸直腸癌\\n非小細胞肺癌\\n頭頸部扁平上皮癌...',\n",
" '胆道癌',\n",
" '転移性去勢抵抗性前立腺癌',\n",
" 'HER2陽性の進行性又は転移性の胆道癌',\n",
" '進行期乳房外パジェット病',\n",
" '多発性骨髄腫',\n",
" '転移性去勢抵抗性前立腺癌',\n",
" '非小細胞肺癌',\n",
" '濾胞性リンパ腫',\n",
" '非小細胞肺癌',\n",
" '未治療又は1レジメンの全身治療歴を有するIDH1変異陽性の局所進行又は転移性の通常型軟骨肉腫',\n",
" '標準治療がない、または標準治療に不応もしくは不耐の根治切除不能な進行・再発固形がん患者',\n",
" '扁平上皮非小細胞肺癌',\n",
" '子宮頸癌',\n",
" '非小細胞肺癌',\n",
" '大細胞型B細胞リンパ腫',\n",
" '非ホジキンリンパ腫\\n難治性B細胞性非ホジキンリンパ腫\\n再発B細胞性非ホジキンリンパ腫',\n",
" '多発性骨髄腫、慢性骨髄性白血病',\n",
" 'HER2発現を有する固形癌',\n",
" '限局型小細胞肺癌',\n",
" '結腸直腸癌、膵管腺癌、胆道癌',\n",
" '\"再発又は難治性の多発性骨髄腫\\n治療歴のあるアミロイド軽鎖（AL）アミロイドーシス\"',\n",
" '固形癌',\n",
" '進行性又は転移性非扁平上皮非小細胞肺癌',\n",
" '未治療のFLIPI 2～5の濾胞性リンパ腫患者',\n",
" '再発進行原発性肺腺癌',\n",
" '臨床病期II期またはIII期と診断され、かつ切除可能な乳癌',\n",
" '臨床病期II期またはIII期と診断され、かつ切除可能な乳癌',\n",
" '乳がん',\n",
" '食道癌（扁平上皮癌）',\n",
" '多発性骨髄腫',\n",
" '非小細胞肺癌',\n",
" '胃腺癌、食道胃接合部腺癌及び食道腺癌',\n",
" '転移性乳癌（mBC）及び進行または転移性胃又は胃食道接合部又は食道腺癌（mGEAC）患者',\n",
" '進展型小細胞肺癌\\n小細胞肺癌',\n",
" '非小細胞肺癌',\n",
" '進行固形癌',\n",
" '筋層非浸潤性膀胱癌',\n",
" '非小細胞肺癌',\n",
" '去勢抵抗性前立腺癌',\n",
" '進行乳癌',\n",
" '進展型小細胞肺癌',\n",
" '悪性神経膠腫',\n",
" '転移性固形がん\\n再発性固形がん\\n進行性固形がん',\n",
" '成人T細胞白血病・リンパ腫',\n",
" '子宮体がん',\n",
" '非小細胞肺癌',\n",
" '進行小細胞肺癌',\n",
" '卵巣癌・固形がん',\n",
" '転移性結腸直腸癌',\n",
" '未治療の転移性非扁平上皮非小細胞肺癌（NSCLC）',\n",
" '筋層非浸潤性膀胱癌',\n",
" '子宮体癌',\n",
" '転移性前立腺癌',\n",
" '転移性前立腺癌',\n",
" '再発又は難治性の多発性骨髄腫',\n",
" '肺がん、食道がん、胃癌等の固形がん',\n",
" '子宮内膜癌、頭頸部扁平上皮癌、膵管腺癌、大腸癌、肝細胞癌、食道腺癌／食道胃接合部腺癌／胃腺癌、尿...',\n",
" '多発性骨髄腫',\n",
" '成人T細胞白血病リンパ腫',\n",
" '再発又は難治性の多発性骨髄腫',\n",
" 'HER2 陽性又は HER2 低発現の切除不能又は転移性乳癌',\n",
" '進行固形がん',\n",
" '子宮体癌',\n",
" '悪性胸膜中皮腫',\n",
" '乳癌',\n",
" '非小細胞肺癌',\n",
" '進行固形癌',\n",
" '固形癌',\n",
" '中枢神経系原発リンパ腫',\n",
" '慢性リンパ性白血病／小リンパ球性リンパ腫',\n",
" '悪性黒色腫',\n",
" '再発小細胞肺癌',\n",
" '進行NSCLC 及びその他の固形がん',\n",
" 'ホルモン受容体（HR）陽性ヒト上皮増殖因子受容体2（HER2）陰性の進行または転移乳癌',\n",
" '扁平上皮非小細胞肺がん',\n",
" '転移性非扁平上皮非小細胞肺癌',\n",
" '固形腫瘍及び血液学的悪性腫瘍',\n",
" '非小細胞肺癌',\n",
" '進行性又は転移性の固形がん',\n",
" 'エストロゲン受容体陽性／ヒト上皮増殖因子受容体 2 陰性の進行または転移乳癌',\n",
" '未治療の大細胞型B細胞リンパ腫患者',\n",
" '多発性骨髄腫',\n",
" '乳癌',\n",
" '固形がん',\n",
" '局所進行（切除不能）及び／又は遠隔転移を伴うHER2発現癌',\n",
" '多発性骨髄腫',\n",
" '再発小細胞肺癌（SCLC）',\n",
" '神経内分泌腫瘍（NEN）',\n",
" '固形癌',\n",
" '組織学的又は細胞学的に確認されたES-SCLC',\n",
" '再発又は難治性濾胞性リンパ腫',\n",
" 'CIでM1のないPSMA-PETによるオリゴ転移性前立腺がん（OMPC）',\n",
" '再発・難治性のマントル細胞リンパ腫又は再発・難治性の前駆B細胞性急性リンパ芽球性白血病',\n",
" '再発または難治性多発性骨髄腫',\n",
" '多発性骨髄腫',\n",
" '限局型小細胞肺癌\\n小細胞肺癌',\n",
" '本治験の被験者は，アジアの実施医療機関から参加する，確立された治療が無効である又はその適応ではな...',\n",
" '再発膠芽腫',\n",
" '局所進行又は転移性固形癌',\n",
" '局所進行頭頸部扁平上皮癌',\n",
" 'MTAP 欠損固形がん患者',\n",
" '古典的ホジキンリンパ腫及び非ホジキンリンパ腫',\n",
" '胃癌、食道胃接合部癌、膵管腺癌',\n",
" '転移性去勢感受性前立腺癌',\n",
" '局所進行頭頸部扁平上皮癌',\n",
" '初発膠芽腫',\n",
" '肝細胞癌，膵管腺癌，胆道癌，食道扁平上皮癌，乳癌，頭頚部扁平上皮癌',\n",
" '固形がん',\n",
" '多発性骨髄腫',\n",
" '手術不能かつ既存治療不応の進行・再発固形がん',\n",
" '早期又は進行／転移性の固形がん',\n",
" '非小細胞肺癌',\n",
" '非小細胞肺癌\\n転移性腫瘍',\n",
" '固形癌',\n",
" '新生物',\n",
" '胆道癌',\n",
" '潜在的にSEZ6を発現する進行固形がん',\n",
" '肺外神経内分泌癌（ただしメルケル細胞癌，甲状腺髄様癌又はグレード3の神経内分泌腫瘍を除く）\\n肺の大...',\n",
" '非小細胞肺癌（NSCLC）',\n",
" 'HER2 TKD変異を有する切除不能，局所進行又は転移性非扁平上皮非小細胞肺癌',\n",
" '再発又は難治性の多発性骨髄腫（RRMM）',\n",
" '多発性骨髄腫',\n",
" 'HER2低発現の胃腺癌又は胃食道接合部腺癌又は食道腺癌',\n",
" '未治療多発性骨髄腫',\n",
" '再発又は難治性のT細胞リンパ腫及び慢性リンパ性白血病/小リンパ球性リンパ腫',\n",
" '消化器（消化管・肝胆膵）神経内分泌癌',\n",
" '直腸がん',\n",
" '切除不能な胸膜中皮腫',\n",
" '乳がん、早期乳がん',\n",
" '切除不能な転移性結腸・直腸癌',\n",
" '悪性固形腫瘍',\n",
" '局所進行子宮頸癌',\n",
" '遠隔転移を有する膵がん',\n",
" '• パート1: 局所進行又は転移性固形癌\\n• パート2: 胃腺癌、食道胃接合部腺癌、食道腺癌又は非小細胞肺癌',\n",
" '非小細胞肺癌',\n",
" '進行性又は転移性がん',\n",
" '再発及び難治性の多発性骨髄腫',\n",
" '大細胞型B細胞性リンパ腫、濾胞性リンパ腫',\n",
" '進行性又は転移性の固形がん、進行性又は転移性の食道癌、進行性又は転移性の頭頸部扁平上皮癌',\n",
" '再発又は遠隔転移を有する頭頸部癌',\n",
" '再発又は難治性のT細胞リンパ腫',\n",
" '急性白血病（慢性白血病の急性転化例を含む）、悪性リンパ腫\\nただし、L-アスパラギナーゼ製剤に過敏症...',\n",
" '黒色腫',\n",
" '固形がん（Arm 1）、非小細胞肺癌（Arm 2及びArm 3）',\n",
" 'EGFRのエクソン20挿入変異を有する局所進行又は転移性非扁平上皮非小細胞肺癌',\n",
" 'EGFRのエクソン20挿入変異及びUncommon/Single又はCompound変異を有する局所進行又は転移性非小細胞肺癌',\n",
" '用量漸増部分：組織型を問わず，KRAS wt増幅又はKRAS G12V変異を有する治療選択肢が限られている固形癌...',\n",
" 'B細胞性非ホジキンリンパ腫',\n",
" '再発若しくは転移性又は切除不能な局所進行の有棘細胞癌',\n",
" '胃腺がん, 胃食道接合部(GEJ)腺がん',\n",
" '前立腺癌',\n",
" '臨床的に遠隔転移のない膵がん',\n",
" '癌関連静脈血栓塞栓症',\n",
" '尿路上皮癌',\n",
" 'CRPCコホート\\n転移性去勢抵抗性前立腺癌',\n",
" '標準治療がない又は不応若しくは不耐の進行再発と診断されたユーイング肉腫又は固形がん',\n",
" 'KRAS wt増幅を有する固形癌（GAC，EAC，及びGEJAC）\\n組織型を問わず，KRAS wt増幅又はKRAS G12V変異を...',\n",
" '癌',\n",
" '中枢神経系原発悪性リンパ腫',\n",
" '肝細胞癌、胆道癌',\n",
" 'エストロゲン受容体陽性／ヒト上皮増殖因子受容体2陰性の進行乳癌',\n",
" '血液がん',\n",
" '筋層浸潤性膀胱癌',\n",
" 'びまん性大細胞型B細胞リンパ腫 ',\n",
" '非小細胞肺癌',\n",
" '神経膠腫',\n",
" '局所進行、転移性、又は切除不能な固形癌',\n",
" '皮膚血管肉腫',\n",
" '局所進行又は転移性固形がん',\n",
" '胆道癌',\n",
" '固形癌',\n",
" '多発性骨髄腫',\n",
" '多発性骨髄腫',\n",
" '結腸癌',\n",
" '胃癌\\n食道胃接合部癌\\n膵臓線癌\\n食道線癌',\n",
" '進行切除不能肝細胞癌',\n",
" '頭頸部癌',\n",
" '卵巣癌',\n",
" '胃腺癌、胃食道接合部（GEJ）腺癌、及び食道腺癌を含む進行性又は転移性GEA患者',\n",
" '筋層非浸潤性膀胱癌',\n",
" '未治療の切除不能または再発胸腺癌',\n",
" '乳癌',\n",
" '局所進行又は転移性非扁平上皮非小細胞肺癌',\n",
" '膀胱がん\\n転移性腫瘍\\n尿管癌',\n",
" '再発・難治性の局所進行性・転移性乳がん及びトリプルネガティブ乳がん',\n",
" '乳がん、早期乳がん',\n",
" '進行性の切除不能又は転移性MSIhi 又はdMMR固形がん，結腸直腸がん（CRC）',\n",
" '多発性骨髄腫',\n",
" '固形癌',\n",
" '局所進行切除不能又は転移性の胃腺癌又は食道胃接合部腺癌',\n",
" 'IDH野生型神経膠腫（グレードⅢ）（退形成性星細胞腫）',\n",
" 'トリプルネガティブ乳がん',\n",
" 'EGFR遺伝子変異を有する非小細胞肺癌患者',\n",
" 'FGFR2遺伝子融合又は再構成を伴う胆管癌',\n",
" '非小細胞肺癌',\n",
" '多発性骨髄腫',\n",
" '低悪性度神経膠腫、膵癌',\n",
" '進行固形癌、非小細胞肺癌、頭頚部腫瘍',\n",
" '固形がん',\n",
" '卵巣癌',\n",
" '肝転移を有する進行又は再発固形癌の患者',\n",
" 'DLL3を発現する小細胞肺癌及びその他の神経内分泌腫瘍',\n",
" '卵巣扁平上皮癌',\n",
" '進行性固形がん',\n",
" 'BRAF V600変異を有する局所進行切除不能又は転移性黒色腫、治療歴のないBRAF V600E変異を有する転移性結...',\n",
" '進行又は転移性固形がん',\n",
" '肝細胞癌',\n",
" '食道がん、胃がん',\n",
" 'エストロゲン受容体陽性／ヒト上皮増殖因子受容体2陰性の進行乳癌',\n",
" 'LTK融合遺伝子陽性の進行非小細胞肺癌（NSCLC）',\n",
" '多発性骨髄腫患者',\n",
" '進行，切除不能又は転移性固形癌',\n",
" '食道扁平上皮癌',\n",
" '再発又は難治性多発性骨髄腫',\n",
" '固形癌',\n",
" 'HER2 陽性転移性結腸直腸癌',\n",
" '乳癌',\n",
" 'がん悪液質',\n",
" '切除不能胆道癌',\n",
" '進行性尿路上皮癌',\n",
" '多発性骨髄腫',\n",
" '二次性中枢神経系リンパ腫',\n",
" '小細胞肺癌及びその他の神経内分泌癌',\n",
" 'ミスマッチ修復異常を認める切除可能なStage II/III およびStage I 直腸癌',\n",
" '局所進行頭頸部扁平上皮癌',\n",
" '用量漸増コホート：固形がん\\n拡大コホート1：結腸・直腸がん\\n拡大コホート2：TMEM180陽性の結腸・直腸...',\n",
" '膀胱新生物受容体、線維芽細胞増殖因子',\n",
" '初発の多発性骨髄腫',\n",
" '切除不能進行・再発胃癌',\n",
" '非小細胞肺癌',\n",
" '乳房外パジェット病',\n",
" '頭頸部がんのがん治療に伴う口腔粘膜炎の疼痛 ',\n",
" '非小細胞肺癌',\n",
" '非小細胞肺癌',\n",
" '子宮体癌\\n胃癌\\n転移性去勢抵抗性前立腺癌\\n卵巣癌\\n大腸癌\\n尿路上皮癌\\n胆道癌',\n",
" '特定の進行固形癌',\n",
" '結腸・直腸癌遠隔転移の治癒切除を予定している患者',\n",
" '成熟B細胞性リンパ腫',\n",
" '非小細胞肺癌',\n",
" '多発性骨髄腫',\n",
" '再発及び／又は難治性B細胞性非ホジキンリンパ腫（B-NHL）及び再発及び／又は難治性B細胞性急性リンパ芽...',\n",
" '結腸直腸癌',\n",
" '固形がん',\n",
" '固形癌',\n",
" '・肉腫、ユーイング 、・新生物転移',\n",
" '進行非小細胞肺がん',\n",
" '乳がん',\n",
" '原発性直腸癌',\n",
" '進行非小細胞肺がん\\nEGFR変異\\nHER2変異',\n",
" '肝細胞癌',\n",
" '卵巣がん',\n",
" '非小細胞肺癌 ',\n",
" '多発性骨髄腫',\n",
" '悪性腹水を伴うMSS進行期消化器癌',\n",
" '固形がん',\n",
" '腹膜播種を伴う大腸癌',\n",
" '固形癌',\n",
" '標準治療不応・不耐もしくは再発又は進行HER2陽性骨・軟部肉腫および婦人科悪性腫瘍',\n",
" '進行腎細胞癌及び卵巣癌',\n",
" '悪性胸膜中皮腫',\n",
" '移植後の初発多発性骨髄腫',\n",
" '肝細胞癌',\n",
" '胃癌又は食道胃接合部癌',\n",
" '非小細胞肺癌',\n",
" '局所進行（切除不能）又は転移性乳癌',\n",
" '進行固形癌',\n",
" 'BRAF V600E 変異を有する切除可能大腸癌遠隔転移患者',\n",
" '進行MTAP欠損固形癌',\n",
" 'EGFR 遺伝子変異陽性未治療進行非小細胞肺癌',\n",
" '肺扁平上皮癌',\n",
" '標準治療がない、あるいは標準的治療法に不応又は不耐の固形癌',\n",
" 'Nectin-4陽性固形癌',\n",
" '非小細胞肺癌',\n",
" '胃癌、食道胃接合部癌',\n",
" '筋層浸潤性膀胱癌',\n",
" '進行固形癌',\n",
" '切除不能な局所進行非小細胞肺癌（ステージIII）',\n",
" '胃腺癌，食道胃接合部腺癌，膵腺癌',\n",
" '多発性骨髄腫',\n",
" '非小細胞肺癌を除くALK 融合遺伝子陽性、進行・再発の固形腫瘍',\n",
" '再発又は難治性のB細胞性非ホジキンリンパ腫',\n",
" 'PD-L1高発現（TPSが50%以上）の進行又は転移性非小細胞肺癌',\n",
" 'びまん性大細胞リンパ腫、急性リンパ芽球性白血病、慢性リンパ性白血病',\n",
" '乳癌、胆道癌、卵巣癌、子宮内膜癌',\n",
" '固形癌',\n",
" '進行性又は転移性の固形がん',\n",
" '前立腺癌',\n",
" 'HER2エクソン19又は20の変異を有する非小細胞肺癌',\n",
" '固形がん',\n",
" 'NRG1融合が記録されているNSCLC、膵腺癌、および他のすべての固形腫瘍',\n",
" '悪性胸膜中皮腫',\n",
" '中間期肝細胞癌',\n",
" '局所進行又は転移性固形がん',\n",
" '消化管間質腫瘍',\n",
" '転移性又は切除不能の悪性黒色腫, 転移性又は切除不能の肝細胞癌, 転移性又は切除不能の大腸癌',\n",
" '非小細胞肺癌，進行固形癌，胃食道接合部腺癌，大腸癌',\n",
" '肺扁平上皮癌',\n",
" '非小細胞肺癌（NSCLC），頭頸部扁平上皮癌（HNSCC），その他の固形癌',\n",
" '進行・再発非小細胞肺癌',\n",
" '非小細胞肺癌（NSCLC）',\n",
" '乳がん',\n",
" '中皮腫，NF2 / LATS1 / LATS2 変異を伴う腫瘍，及び機能獲得性YAP / TAZ融合を伴う腫瘍を有する患者',\n",
" 'HER2陽性の胃癌または胃食道接合部癌',\n",
" '再発悪性神経膠腫',\n",
" '固形癌',\n",
" '上皮性卵巣がん（原発性腹膜がん及び卵管がんを含む）',\n",
" '非小細胞肺癌、大腸新生物、子宮内膜新生物、卵巣新生物、膵臓新生物、胆道新生物',\n",
" '【コホートA】BRCA変異陽性の子宮平滑筋肉腫：募集中\\n【コホートB】BRCA変異陰性・HRD陽性の子宮平滑筋...',\n",
" '未治療の治癒切除不能な膵がん患者（ 遠隔転移例・切除不能局所進行膵がん）を対象とし、術後の再発症例...',\n",
" '成人のROS1 融合遺伝子陽性の進行または転移性非小細胞肺癌(NSCLC)患者',\n",
" '転移性食道扁平上皮癌',\n",
" '多発性骨髄腫',\n",
" '進行固形がん',\n",
" '再発又は難治性の多発性骨髄腫（RRMM）',\n",
" '胃癌',\n",
" '進行固形癌',\n",
" '・進行固形癌 \\n・KRAS p.G12C変異を有する',\n",
" 'LK、ROS1またはNTRK1-3の遺伝子再構成を有する進行固形癌患者',\n",
" '筋層非浸潤性膀胱がん',\n",
" '固形がん及び血液がん（AML, MDS, DLBCL）',\n",
" '成人 T 細胞白血病・リンパ腫',\n",
" 'ER陽性HER2陰性乳癌',\n",
" '進行固形癌',\n",
" '筋層浸潤性膀胱癌',\n",
" '進行又は転移性非小細胞肺癌',\n",
" '再発又は難治性の大細胞型B細胞リンパ腫',\n",
" 'GPC3発現手術不能進行再発卵巣明細胞癌で腹膜播種を有する患者',\n",
" '筋層非浸潤性膀胱癌',\n",
" '前立腺がん',\n",
" '非ホジキンリンパ腫 （びまん性大細胞型B細胞リンパ腫）',\n",
" '膀胱癌',\n",
" '表在性食道癌',\n",
" '多発性骨髄腫',\n",
" '膵臓がん',\n",
" '局所進行または転移性ER陽性HER2陰性乳癌，局所進行または転移性去勢抵抗性前立腺癌，局所進行または転...',\n",
" '頭頸部扁平上皮がん',\n",
" '固形癌（非小細胞肺癌など）',\n",
" '胃腺癌、胃食道接合部腺癌又は食道腺癌',\n",
" '膠芽腫',\n",
" '4型進行胃癌',\n",
" '悪性黒色腫',\n",
" '進行性悪性黒色腫']"
]
},
"execution_count": 58,
"metadata": {},
"output_type": "execute_result"
}
],
"source": [
"target_list"
]
},
{
"cell_type": "code",
"execution_count": 61,
"metadata": {},
"outputs": [],
"source": [
"with open('test.txt', 'w') as f:\n",
" print(target_list, file=f)"
]
},
{
"cell_type": "code",
"execution_count": 70,
"metadata": {},
"outputs": [],
"source": [
"# Target列を分割する関数\n",
"def split_target(target):\n",
" # 指定された区切り文字で分割\n",
" split_words = re.split(r'[,\\n、・及びおよび又はまたは]+', target)\n",
" # 空白文字を除外してリストとして返す\n",
" return [word.strip() for word in split_words if word.strip()]"
]
},
{
"cell_type": "code",
"execution_count": 73,
"metadata": {},
"outputs": [
{
"data": {
"text/plain": [
"['PD-L1高発現（TPSが50%以上）の進行', '転移性非小細胞肺癌', '神経膠腫']"
]
},
"execution_count": 73,
"metadata": {},
"output_type": "execute_result"
}
],
"source": [
"split_target('PD-L1高発現（TPSが50%以上）の進行・転移性非小細胞肺癌、神経膠腫')"
]
},
{
"cell_type": "code",
"execution_count": 74,
"metadata": {},
"outputs": [],
"source": [
"# Target列を分割してTargetWord列を追加\n",
"basedf['TargetWord'] = basedf['Target'].apply(split_target)\n"
]
},
{
"cell_type": "code",
"execution_count": 75,
"metadata": {},
"outputs": [
{
"data": {
"text/html": [
"<div>\n",
"<style scoped>\n",
" .dataframe tbody tr th:only-of-type {\n",
" vertical-align: middle;\n",
" }\n",
"\n",
" .dataframe tbody tr th {\n",
" vertical-align: top;\n",
" }\n",
"\n",
" .dataframe thead th {\n",
" text-align: right;\n",
" }\n",
"</style>\n",
"<table border=\"1\" class=\"dataframe\">\n",
" <thead>\n",
" <tr style=\"text-align: right;\">\n",
" <th></th>\n",
" <th>JRCT ID</th>\n",
" <th>NCT No</th>\n",
" <th>JapicCTI No</th>\n",
" <th>Title</th>\n",
" <th>Target</th>\n",
" <th>研究・治験の目的</th>\n",
" <th>試験等のフェーズ</th>\n",
" <th>試験の種類</th>\n",
" <th>無作為化</th>\n",
" <th>盲検化</th>\n",
" <th>...</th>\n",
" <th>purpose</th>\n",
" <th>Inclusion Criteria</th>\n",
" <th>Exclusion Criteria</th>\n",
" <th>Age Minimum</th>\n",
" <th>Age Maximum</th>\n",
" <th>Gender</th>\n",
" <th>Discontinuation Criteria</th>\n",
" <th>Keyword</th>\n",
" <th>Intervention(s)</th>\n",
" <th>TargetWord</th>\n",
" </tr>\n",
" </thead>\n",
" <tbody>\n",
" <tr>\n",
" <th>0</th>\n",
" <td>jRCT2021240039</td>\n",
" <td>NCT06632951</td>\n",
" <td>NaN</td>\n",
" <td>[M25-204]転移性尿路上皮癌患者を対象に，livmoniplimab とbudigal...</td>\n",
" <td>尿路上皮癌</td>\n",
" <td>主要目的：全生存期間（以下「OS」）を指標として，livmoniplimab と budig...</td>\n",
" <td>2</td>\n",
" <td>NaN</td>\n",
" <td>無作為化比較</td>\n",
" <td>非盲検</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>-Participant has histologically or cytological...</td>\n",
" <td>-Participant has received more than 1 prior ch...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>-Arm 1: Livmoniplimab (Dose A) + Budigalimab\\r...</td>\n",
" <td>[尿路上皮癌]</td>\n",
" </tr>\n",
" <tr>\n",
" <th>4</th>\n",
" <td>jRCT2031240512</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>フッ化ピリミジン製剤及びプラチナ製剤を含む一次治療に不応・不耐となった切除不能進行・再発胃癌...</td>\n",
" <td>切除不能進行・再発胃癌</td>\n",
" <td>フッ化ピリミジン・プラチナ系薬剤に不応・不耐の切除不能進行・再発胃癌被験者を対象として、ベバ...</td>\n",
" <td>1</td>\n",
" <td>NaN</td>\n",
" <td>無作為化比較</td>\n",
" <td>非盲検</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>1)\\tAge between 18 and 75 years.\\r\\n2)\\tPerfor...</td>\n",
" <td>1)\\tPrior treatment history with paclitaxel, r...</td>\n",
" <td>18age old over</td>\n",
" <td>75age old under</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>Safety Part (Dose Escalation):\\r\\nLevel 0: Bev...</td>\n",
" <td>[切除不能進行, 再発胃癌]</td>\n",
" </tr>\n",
" <tr>\n",
" <th>7</th>\n",
" <td>jRCT2051240197</td>\n",
" <td>NCT06692738</td>\n",
" <td>NaN</td>\n",
" <td>PD-L1 陽性の転移性扁平上皮非小細胞肺癌患者に対する一次治療として、Rilvegosto...</td>\n",
" <td>非小細胞肺癌</td>\n",
" <td>Treatment</td>\n",
" <td>3</td>\n",
" <td>NaN</td>\n",
" <td>無作為化比較</td>\n",
" <td>二重盲検</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>- Histologically or cytologically documented s...</td>\n",
" <td>- Presence of small cell and neuroendocrine hi...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>Participants will be randomized in a 1:1 ratio...</td>\n",
" <td>[非小細胞肺癌]</td>\n",
" </tr>\n",
" <tr>\n",
" <th>8</th>\n",
" <td>jRCT2031240508</td>\n",
" <td>NCT06573294</td>\n",
" <td>NaN</td>\n",
" <td>悪性固形癌患者を対象にGEN1057の安全性及び抗腫瘍活性を評価するヒト初回投与、非盲検、用...</td>\n",
" <td>進行性悪性固形癌\\n転移性悪性固形癌</td>\n",
" <td>本第I相試験の目的は、転移性又は進行性病変を有する悪性固形癌患者を対象に、GEN1057を単...</td>\n",
" <td>1</td>\n",
" <td>NaN</td>\n",
" <td>単一群</td>\n",
" <td>非盲検</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>-Advanced and/or metastatic solid tumors, who ...</td>\n",
" <td>Has been exposed to any of the following prior...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>GEN1057 monotherapy will be administered intra...</td>\n",
" <td>[進行性悪性固形癌, 転移性悪性固形癌]</td>\n",
" </tr>\n",
" <tr>\n",
" <th>12</th>\n",
" <td>jRCT2041240130</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>中等度-高度PONV発症リスクを有する肺切除術予定患者の周術期管理におけるGranisetr...</td>\n",
" <td>肺がん</td>\n",
" <td>全身麻酔を要する肺切除術周術期における標準制吐療法であるグラニセトロン(Granisetro...</td>\n",
" <td>2</td>\n",
" <td>NaN</td>\n",
" <td>無作為化比較</td>\n",
" <td>非盲検</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>(1) Patients scheduled to undergo anatomical l...</td>\n",
" <td>(1) Patients with a history of allergy to the ...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>Treatment group\\r\\nAdminister GRA 1mg intraven...</td>\n",
" <td>[肺がん]</td>\n",
" </tr>\n",
" <tr>\n",
" <th>...</th>\n",
" <td>...</td>\n",
" <td>...</td>\n",
" <td>...</td>\n",
" <td>...</td>\n",
" <td>...</td>\n",
" <td>...</td>\n",
" <td>...</td>\n",
" <td>...</td>\n",
" <td>...</td>\n",
" <td>...</td>\n",
" <td>...</td>\n",
" <td>...</td>\n",
" <td>...</td>\n",
" <td>...</td>\n",
" <td>...</td>\n",
" <td>...</td>\n",
" <td>...</td>\n",
" <td>...</td>\n",
" <td>...</td>\n",
" <td>...</td>\n",
" <td>...</td>\n",
" </tr>\n",
" <tr>\n",
" <th>974</th>\n",
" <td>jRCT2031200203</td>\n",
" <td>NCT04379596</td>\n",
" <td>NaN</td>\n",
" <td>HER2発現の成人胃癌患者を対象としてトラスツズマブ デルクステカン（T-DXd）の単剤療法...</td>\n",
" <td>胃腺癌、胃食道接合部腺癌又は食道腺癌</td>\n",
" <td>DESTINY-Gastric03は、HER2発現の進行・転移性胃癌・胃食道接合部（GEJ）...</td>\n",
" <td>1-2</td>\n",
" <td>NaN</td>\n",
" <td>無作為化比較</td>\n",
" <td>非盲検</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>1. Male and female participants must be at lea...</td>\n",
" <td>1. History of active primary immunodeficiency,...</td>\n",
" <td>18age old over</td>\n",
" <td>130age old under</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>Experimental: Arm 1A: T-DXd and 5-fluorouracil...</td>\n",
" <td>[胃腺癌, 胃食道接合部腺癌, 食道腺癌]</td>\n",
" </tr>\n",
" <tr>\n",
" <th>981</th>\n",
" <td>jRCT2031200153</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>Cellm-001による初発膠芽腫治療効果無作為比較対照試験</td>\n",
" <td>膠芽腫</td>\n",
" <td>脳腫瘍のうち、初発悪性膠芽腫に対する自家脳腫瘍免疫賦活剤であるCellm-001について、術...</td>\n",
" <td>3</td>\n",
" <td>NaN</td>\n",
" <td>無作為化比較</td>\n",
" <td>二重盲検</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>(1) 18 years old or older and 75 years old or ...</td>\n",
" <td>(1) Systemic administration of corticosteroids...</td>\n",
" <td>18age old over</td>\n",
" <td>75age old under</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>Inject the investigational drug (Cellm-001 or ...</td>\n",
" <td>[膠芽腫]</td>\n",
" </tr>\n",
" <tr>\n",
" <th>996</th>\n",
" <td>jRCT2031200087</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>4型進行胃癌に対する術後または周術期補助化学療法としての全身・腹腔内併用化学療法と全身化学療...</td>\n",
" <td>4型進行胃癌</td>\n",
" <td>術後腹膜播種のリスクが高い4型進行胃癌を対象として、全身・腹腔内併用化学療法の全身化学療法に...</td>\n",
" <td>3</td>\n",
" <td>NaN</td>\n",
" <td>無作為化比較</td>\n",
" <td>非盲検</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>Confirmation before temporary registration\\r\\n...</td>\n",
" <td>1)\\tSimultaneously active double cancer.\\r\\n2)...</td>\n",
" <td>20age old over</td>\n",
" <td>75age old under</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>S-1 monotherapy\\r\\noral S-1 80 mg/m2/day on da...</td>\n",
" <td>[4型進行胃癌]</td>\n",
" </tr>\n",
" <tr>\n",
" <th>1053</th>\n",
" <td>jRCT2033190086</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>悪性黒色腫患者を対象としたインターロイキン12発現型遺伝子組換え単純ヘルペスウイルス１型の第...</td>\n",
" <td>悪性黒色腫</td>\n",
" <td>第Ⅰ相パート：進行期の悪性黒色腫患者を対象として、ヒトIL-12発現型遺伝子組換え単純ヘルペ...</td>\n",
" <td>1-2</td>\n",
" <td>NaN</td>\n",
" <td>単一群</td>\n",
" <td>非盲検</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>(Phase 1)\\r\\n1) Histologically confirmed malig...</td>\n",
" <td>(Phase 1 and 2)\\r\\n1) Patients who have brain ...</td>\n",
" <td>20age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>malignamt melanoma, advanced stage</td>\n",
" <td>Test drug (T-hIL12) will be administered into ...</td>\n",
" <td>[悪性黒色腫]</td>\n",
" </tr>\n",
" <tr>\n",
" <th>1067</th>\n",
" <td>jRCT2051190009</td>\n",
" <td>NCT03818893</td>\n",
" <td>JapicCTI-194618</td>\n",
" <td>進行性悪性黒色腫患者を対象としたGEN0101の皮内投与と、ペムブロリズマブ（抗PD-1抗体...</td>\n",
" <td>進行性悪性黒色腫</td>\n",
" <td>抗PD-1抗体治療でSDが確定した、またはPDとなった患者を対象とし、非盲検下でGEN010...</td>\n",
" <td>1-2</td>\n",
" <td>NaN</td>\n",
" <td>非無作為化比較</td>\n",
" <td>非盲検</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>Inclusion criteria \\r\\nPatients meeting all of...</td>\n",
" <td>Exclusion criteria\\r\\nPatients meeting any of ...</td>\n",
" <td>20age old over</td>\n",
" <td>86age old not</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>advanced melanoma</td>\n",
" <td>combination therapy of intracutaneous GEN0101 ...</td>\n",
" <td>[進行性悪性黒色腫]</td>\n",
" </tr>\n",
" </tbody>\n",
"</table>\n",
"<p>416 rows × 39 columns</p>\n",
"</div>"
],
"text/plain": [
" JRCT ID NCT No JapicCTI No \\\n",
"0 jRCT2021240039 NCT06632951 NaN \n",
"4 jRCT2031240512 NaN NaN \n",
"7 jRCT2051240197 NCT06692738 NaN \n",
"8 jRCT2031240508 NCT06573294 NaN \n",
"12 jRCT2041240130 NaN NaN \n",
"... ... ... ... \n",
"974 jRCT2031200203 NCT04379596 NaN \n",
"981 jRCT2031200153 NaN NaN \n",
"996 jRCT2031200087 NaN NaN \n",
"1053 jRCT2033190086 NaN NaN \n",
"1067 jRCT2051190009 NCT03818893 JapicCTI-194618 \n",
"\n",
" Title Target \\\n",
"0 [M25-204]転移性尿路上皮癌患者を対象に，livmoniplimab とbudigal... 尿路上皮癌 \n",
"4 フッ化ピリミジン製剤及びプラチナ製剤を含む一次治療に不応・不耐となった切除不能進行・再発胃癌... 切除不能進行・再発胃癌 \n",
"7 PD-L1 陽性の転移性扁平上皮非小細胞肺癌患者に対する一次治療として、Rilvegosto... 非小細胞肺癌 \n",
"8 悪性固形癌患者を対象にGEN1057の安全性及び抗腫瘍活性を評価するヒト初回投与、非盲検、用... 進行性悪性固形癌\\n転移性悪性固形癌 \n",
"12 中等度-高度PONV発症リスクを有する肺切除術予定患者の周術期管理におけるGranisetr... 肺がん \n",
"... ... ... \n",
"974 HER2発現の成人胃癌患者を対象としてトラスツズマブ デルクステカン（T-DXd）の単剤療法... 胃腺癌、胃食道接合部腺癌又は食道腺癌 \n",
"981 Cellm-001による初発膠芽腫治療効果無作為比較対照試験 膠芽腫 \n",
"996 4型進行胃癌に対する術後または周術期補助化学療法としての全身・腹腔内併用化学療法と全身化学療... 4型進行胃癌 \n",
"1053 悪性黒色腫患者を対象としたインターロイキン12発現型遺伝子組換え単純ヘルペスウイルス１型の第... 悪性黒色腫 \n",
"1067 進行性悪性黒色腫患者を対象としたGEN0101の皮内投与と、ペムブロリズマブ（抗PD-1抗体... 進行性悪性黒色腫 \n",
"\n",
" 研究・治験の目的 試験等のフェーズ 試験の種類 \\\n",
"0 主要目的：全生存期間（以下「OS」）を指標として，livmoniplimab と budig... 2 NaN \n",
"4 フッ化ピリミジン・プラチナ系薬剤に不応・不耐の切除不能進行・再発胃癌被験者を対象として、ベバ... 1 NaN \n",
"7 Treatment 3 NaN \n",
"8 本第I相試験の目的は、転移性又は進行性病変を有する悪性固形癌患者を対象に、GEN1057を単... 1 NaN \n",
"12 全身麻酔を要する肺切除術周術期における標準制吐療法であるグラニセトロン(Granisetro... 2 NaN \n",
"... ... ... ... \n",
"974 DESTINY-Gastric03は、HER2発現の進行・転移性胃癌・胃食道接合部（GEJ）... 1-2 NaN \n",
"981 脳腫瘍のうち、初発悪性膠芽腫に対する自家脳腫瘍免疫賦活剤であるCellm-001について、術... 3 NaN \n",
"996 術後腹膜播種のリスクが高い4型進行胃癌を対象として、全身・腹腔内併用化学療法の全身化学療法に... 3 NaN \n",
"1053 第Ⅰ相パート：進行期の悪性黒色腫患者を対象として、ヒトIL-12発現型遺伝子組換え単純ヘルペ... 1-2 NaN \n",
"1067 抗PD-1抗体治療でSDが確定した、またはPDとなった患者を対象とし、非盲検下でGEN010... 1-2 NaN \n",
"\n",
" 無作為化 盲検化 ... purpose \\\n",
"0 無作為化比較 非盲検 ... treatment purpose \n",
"4 無作為化比較 非盲検 ... treatment purpose \n",
"7 無作為化比較 二重盲検 ... treatment purpose \n",
"8 単一群 非盲検 ... treatment purpose \n",
"12 無作為化比較 非盲検 ... treatment purpose \n",
"... ... ... ... ... \n",
"974 無作為化比較 非盲検 ... treatment purpose \n",
"981 無作為化比較 二重盲検 ... treatment purpose \n",
"996 無作為化比較 非盲検 ... treatment purpose \n",
"1053 単一群 非盲検 ... treatment purpose \n",
"1067 非無作為化比較 非盲検 ... treatment purpose \n",
"\n",
" Inclusion Criteria \\\n",
"0 -Participant has histologically or cytological... \n",
"4 1)\\tAge between 18 and 75 years.\\r\\n2)\\tPerfor... \n",
"7 - Histologically or cytologically documented s... \n",
"8 -Advanced and/or metastatic solid tumors, who ... \n",
"12 (1) Patients scheduled to undergo anatomical l... \n",
"... ... \n",
"974 1. Male and female participants must be at lea... \n",
"981 (1) 18 years old or older and 75 years old or ... \n",
"996 Confirmation before temporary registration\\r\\n... \n",
"1053 (Phase 1)\\r\\n1) Histologically confirmed malig... \n",
"1067 Inclusion criteria \\r\\nPatients meeting all of... \n",
"\n",
" Exclusion Criteria Age Minimum \\\n",
"0 -Participant has received more than 1 prior ch... 18age old over \n",
"4 1)\\tPrior treatment history with paclitaxel, r... 18age old over \n",
"7 - Presence of small cell and neuroendocrine hi... 18age old over \n",
"8 Has been exposed to any of the following prior... 18age old over \n",
"12 (1) Patients with a history of allergy to the ... 18age old over \n",
"... ... ... \n",
"974 1. History of active primary immunodeficiency,... 18age old over \n",
"981 (1) Systemic administration of corticosteroids... 18age old over \n",
"996 1)\\tSimultaneously active double cancer.\\r\\n2)... 20age old over \n",
"1053 (Phase 1 and 2)\\r\\n1) Patients who have brain ... 20age old over \n",
"1067 Exclusion criteria\\r\\nPatients meeting any of ... 20age old over \n",
"\n",
" Age Maximum Gender Discontinuation Criteria \\\n",
"0 No limit Both NaN \n",
"4 75age old under Both NaN \n",
"7 No limit Both NaN \n",
"8 No limit Both NaN \n",
"12 No limit Both NaN \n",
"... ... ... ... \n",
"974 130age old under Both NaN \n",
"981 75age old under Both NaN \n",
"996 75age old under Both NaN \n",
"1053 No limit Both NaN \n",
"1067 86age old not Both NaN \n",
"\n",
" Keyword \\\n",
"0 NaN \n",
"4 NaN \n",
"7 NaN \n",
"8 NaN \n",
"12 NaN \n",
"... ... \n",
"974 NaN \n",
"981 NaN \n",
"996 NaN \n",
"1053 malignamt melanoma, advanced stage \n",
"1067 advanced melanoma \n",
"\n",
" Intervention(s) TargetWord \n",
"0 -Arm 1: Livmoniplimab (Dose A) + Budigalimab\\r... [尿路上皮癌] \n",
"4 Safety Part (Dose Escalation):\\r\\nLevel 0: Bev... [切除不能進行, 再発胃癌] \n",
"7 Participants will be randomized in a 1:1 ratio... [非小細胞肺癌] \n",
"8 GEN1057 monotherapy will be administered intra... [進行性悪性固形癌, 転移性悪性固形癌] \n",
"12 Treatment group\\r\\nAdminister GRA 1mg intraven... [肺がん] \n",
"... ... ... \n",
"974 Experimental: Arm 1A: T-DXd and 5-fluorouracil... [胃腺癌, 胃食道接合部腺癌, 食道腺癌] \n",
"981 Inject the investigational drug (Cellm-001 or ... [膠芽腫] \n",
"996 S-1 monotherapy\\r\\noral S-1 80 mg/m2/day on da... [4型進行胃癌] \n",
"1053 Test drug (T-hIL12) will be administered into ... [悪性黒色腫] \n",
"1067 combination therapy of intracutaneous GEN0101 ... [進行性悪性黒色腫] \n",
"\n",
"[416 rows x 39 columns]"
]
},
"execution_count": 75,
"metadata": {},
"output_type": "execute_result"
}
],
"source": [
"basedf"
]
},
{
"cell_type": "code",
"execution_count": null,
"metadata": {},
"outputs": [],
"source": []
}
],
"metadata": {
"kernelspec": {
"display_name": "gradio",
"language": "python",
"name": "python3"
},
"language_info": {
"codemirror_mode": {
"name": "ipython",
"version": 3
},
"file_extension": ".py",
"mimetype": "text/x-python",
"name": "python",
"nbconvert_exporter": "python",
"pygments_lexer": "ipython3",
"version": "3.12.3"
}
},
"nbformat": 4,
"nbformat_minor": 2
}
|